

REFERENCES

- Abdi Ghavidel, A., Aghamiri, S., Raei, P., Mohammadi-Yeganeh, S., Noori, E., Bandehpour, M., Kazemi, B., & Jajarmi, V. (2024). Recent Advances in CRISPR/Cas9-Mediated Genome Editing in Leishmania Strains. *Acta Parasitologica*, 69(1), 121–134. <https://doi.org/10.1007/s11686-023-00756-0>
- Abuchery, B. E., Black, J. A., & da Silva, M. S. (2022). Single-cell transcriptomics reveals hidden information in trypanosomatids. *Trends in Parasitology*, 38(1), 4–6. <https://doi.org/10.1016/j.pt.2021.10.006>
- Afrin, F., Chouhan, G., Islamuddin, M., Want, M. Y., Ozbak, H. A., & Hemeg, H. A. (2019). Cinnamomum cassia exhibits antileishmanial activity against Leishmania donovani infection in vitro and in vivo. *PLOS Neglected Tropical Diseases*, 13(5), e0007227. <https://doi.org/10.1371/journal.pntd.0007227>
- Agnihotri, P., Singh, S. P., Shakya, A. K., & Pratap, J. V. (2016). Biochemical and biophysical characterization of Leishmania donovani gamma-glutamylcysteine synthetase. *Biochemistry and Biophysics Reports*, 8, 127–138. <https://doi.org/10.1016/j.bbrep.2016.08.016>
- Ahmed, F., Soomro, A. M., Chethikkattuveli Salih, A. R., Samantasinghar, A., Asif, A., Kang, I. S., & Choi, K. H. (2022). A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19. *Biomedicine & Pharmacotherapy*, 153, 113350. <https://doi.org/10.1016/j.biopha.2022.113350>
- Akilov, O. E., Kasuboski, R. E., Carter, C. R., & McDowell, M. A. (2007). The role of mannose receptor during experimental leishmaniasis. *Journal of Leukocyte Biology*, 81(5), 1188–1196. <https://doi.org/10.1189/jlb.0706439>
- Ali, R., Tabrez, S., Akand, S. K., Rahman, F., Husein, A., Arish, M., Alqahtani, A. S., Ahmed, M. Z., Husain, M., & Rub, A. (2021). Sesamol Induces Apoptosis-Like Cell Death in Leishmania donovani. *Frontiers in Cellular and Infection Microbiology*, 11. <https://doi.org/10.3389/fcimb.2021.749420>
- Ali, V., Behera, S., Nawaz, A., Equbal, A., & Pandey, K. (2022). *Unique thiol metabolism in trypanosomatids: Redox homeostasis and drug resistance* (pp. 75–155). <https://doi.org/10.1016/bs.apar.2022.04.002>
- Allahverdiyev, A. M., Bagirova, M., Elcicek, S., Koc, R. C., Baydar, S. Y., Findikli, N., & Oztel, O. N. (2011). Adipose Tissue-Derived Mesenchymal Stem Cells as a New Host Cell in Latent Leishmaniasis. *The American Society of Tropical Medicine and Hygiene*, 85(3), 535–539. <https://doi.org/10.4269/ajtmh.2011.11-0037>
- Alpizar-Sosa, E. A., Kumordzi, Y., Wei, W., Whitfield, P. D., Barrett, M. P., & Denny, P. W. (2022). Genome deletions to overcome the directed loss of gene function in Leishmania. *Frontiers in Cellular and Infection Microbiology*, 12. <https://doi.org/10.3389/fcimb.2022.988688>

- Alshehade, S. A., Almoustafa, H. A., Alshawsh, M. A., & Chik, Z. (2024). Flow cytometry-based quantitative analysis of cellular protein expression in apoptosis subpopulations: A protocol. *Heliyon*, *10*(13), e33665. <https://doi.org/10.1016/j.heliyon.2024.e33665>
- Alvar, J., Yactayo, S., & Bern, C. (2006). Leishmaniasis and poverty. *Trends in Parasitology*, *22*(12), 552–557. <https://doi.org/10.1016/j.pt.2006.09.004>
- Apt, W. (2010). Treatment of Chagas Disease. In *American Trypanosomiasis* (pp. 809–825). Elsevier. <https://doi.org/10.1016/B978-0-12-384876-5.00030-7>
- Araújo, C. A., Araújo, A. A., Batista, C. L., Oliveira, M. A. P., Oliveira, V., Lino Junior, R. S., Vinaud, M. C., & Bezerra, J. C. B. (2011). Morphological alterations and growth inhibition of *Leishmania (L.) amazonensis* promastigotes exposed to zidovudine (AZT). *Parasitology Research*, *108*(3), 547–551. <https://doi.org/10.1007/s00436-010-2096-3>
- Ariyanayagam, M. R., Oza, S. L., Mehlert, A., & Fairlamb, A. H. (2003). Bis(glutathionyl)spermine and Other Novel Trypanothione Analogues in *Trypanosoma cruzi*. *Journal of Biological Chemistry*, *278*(30), 27612–27619. <https://doi.org/10.1074/jbc.M302750200>
- Ashraf, M. (2009). Biotechnological approach of improving plant salt tolerance using antioxidants as markers. *Biotechnology Advances*, *27*(1), 84–93. <https://doi.org/10.1016/j.biotechadv.2008.09.003>
- Atwal, P. S., Medina, C. R., Burrage, L. C., & Sutton, V. R. (2016). Nineteen-year follow-up of a patient with severe glutathione synthetase deficiency. *Journal of Human Genetics*, *61*(7), 669–672. <https://doi.org/10.1038/jhg.2016.20>
- Awasthi, A., Mathur, R., Khan, A., Joshi, B. N., Jain, N., Sawant, S., Boppana, R., Mitra, D., & Saha, B. (2003). CD40 Signaling Is Impaired in *L. major*-infected Macrophages and Is Rescued by a p38MAPK Activator Establishing a Host-protective Memory T Cell Response. *The Journal of Experimental Medicine*, *197*(8), 1037–1043. <https://doi.org/10.1084/jem.20022033>
- Azad, N., & Iyer, A. K. V. (2014). Reactive Oxygen Species and Apoptosis. In *Systems Biology of Free Radicals and Antioxidants* (pp. 113–135). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-30018-9_15
- Bácskay, I., Nemes, D., Fenyvesi, F., Váradi, J., Vasvári, G., Fehér, P., Vecsernyés, M., & Ujhelyi, Z. (2018). Role of Cytotoxicity Experiments in Pharmaceutical Development. In *Cytotoxicity*. InTech. <https://doi.org/10.5772/intechopen.72539>
- Baiocco, P., Colotti, G., Franceschini, S., & Ilari, A. (2009). Molecular Basis of Antimony Treatment in Leishmaniasis. *Journal of Medicinal Chemistry*, *52*(8), 2603–2612. <https://doi.org/10.1021/jm900185q>
- Baiocco, P., Poce, G., Alfonso, S., Cocozza, M., Porretta, G. C., Colotti, G., Biava, M., Moraca, F., Botta, M., Yardley, V., Fiorillo, A., Lantella, A., Malatesta, F., & Ilari, A. (2013). Inhibition of *Leishmania infantum* Trypanothione Reductase by Azole-Based Compounds: a Comparative Analysis with Its Physiological Substrate by

- X-ray Crystallography. *ChemMedChem*, 8(7), 1175–1183. <https://doi.org/10.1002/cmdc.201300176>
- Barr, S. D., & Gedamu, L. (2003). Role of Peroxidoxins in *Leishmania chagasi* Survival. *Journal of Biological Chemistry*, 278(12), 10816–10823. <https://doi.org/10.1074/jbc.M212990200>
- Barrie, U., Floyd, K., Datta, A., & Wetzel, D. M. (2024). MAPK/ERK activation in macrophages promotes *Leishmania* internalization and pathogenesis. *Microbes and Infection*, 26(5–6), 105353. <https://doi.org/10.1016/j.micinf.2024.105353>
- Basmaciyan, L., Azas, N., & Casanova, M. (2018). Different apoptosis pathways in *Leishmania* parasites. *Cell Death Discovery*, 4(1), 90. <https://doi.org/10.1038/s41420-018-0092-z>
- Battista, T., Colotti, G., Ilari, A., & Fiorillo, A. (2020). Targeting Trypanothione Reductase, a Key Enzyme in the Redox Trypanosomatid Metabolism, to Develop New Drugs against Leishmaniasis and Trypanosomiasis. *Molecules*, 25(8), 1924. <https://doi.org/10.3390/molecules25081924>
- Bearden, D. T., Neuhauser, M. M., & Garey, K. W. (2001). Telithromycin: An Oral Ketolide for Respiratory Infections. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 21(10), 1204–1222. <https://doi.org/10.1592/phco.21.15.1204.33902>
- Beneke, T., & Gluenz, E. (2019). LeishGEdit: A Method for Rapid Gene Knockout and Tagging Using CRISPR-Cas9. In *Methods in Molecular Biology* (Vol. 1971, pp. 189–210). Humana Press Inc. https://doi.org/10.1007/978-1-4939-9210-2_9
- Beneke, T., Madden, R., Makin, L., Valli, J., Sunter, J., & Gluenz, E. (2017a). A CRISPR Cas9 high-throughput genome editing toolkit for kinetoplastids. *Royal Society Open Science*, 4(5), 170095. <https://doi.org/10.1098/rsos.170095>
- Beneke, T., Madden, R., Makin, L., Valli, J., Sunter, J., & Gluenz, E. (2017b). A CRISPR Cas9 high-throughput genome editing toolkit for kinetoplastids. *Royal Society Open Science*, 4(5), 1–16. <https://doi.org/10.1098/rsos.170095>
- Benítez, D., Medeiros, A., Fiestas, L., Panozzo-Zenere, E. A., Maiwald, F., Prousis, K. C., Roussaki, M., Calogeropoulou, T., Detsi, A., Jaeger, T., Šarlauskas, J., Peterlin Mašič, L., Kunick, C., Labadie, G. R., Flohé, L., & Comini, M. A. (2016). Identification of Novel Chemical Scaffolds Inhibiting Trypanothione Synthetase from Pathogenic Trypanosomatids. *PLOS Neglected Tropical Diseases*, 10(4), e0004617. <https://doi.org/10.1371/journal.pntd.0004617>
- Benson, T. J., McKie, J. H., Garforth, J., Borges, A., Fairlamb, A. H., & Douglas, K. T. (1992). Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. *Biochemical Journal*, 286(1), 9–11. <https://doi.org/10.1042/bj2860009>
- Berman, J. (2005). Miltefosine to treat leishmaniasis. *Expert Opinion on Pharmacotherapy*, 6(8), 1381–1388. <https://doi.org/10.1517/14656566.6.8.1381>

- Berriman, M., Ghedin, E., Hertz-Fowler, C., Blandin, G., Renauld, H., Bartholomeu, D. C., Lennard, N. J., Caler, E., Hamlin, N. E., Haas, B., Böhme, U., Hannick, L., Aslett, M. A., Shallom, J., Marcello, L., Hou, L., Wickstead, B., Alsmark, U. C. M., Arrowsmith, C., ... El-Sayed, N. M. (2005). The Genome of the African Trypanosome *Trypanosoma brucei*. *Science*, *309*(5733), 416–422. <https://doi.org/10.1126/science.1112642>
- BIGGAR, W. (2004). Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. *Neuromuscular Disorders*, *14*(8–9), 476–482. <https://doi.org/10.1016/j.nmd.2004.05.001>
- Blackwell, J. M., Ezekowitz, R. A., Roberts, M. B., Channon, J. Y., Sim, R. B., & Gordon, S. (1985). Macrophage complement and lectin-like receptors bind *Leishmania* in the absence of serum. *The Journal of Experimental Medicine*, *162*(1), 324–331. <https://doi.org/10.1084/jem.162.1.324>
- Blumenstiel, K., Schöneck, R., Yardley, V., Croft, S. L., & Krauth-Siegel, R. L. (1999). Nitrofuran drugs as common subversive substrates of *Trypanosoma cruzi* lipoamide dehydrogenase and trypanothione reductase. *Biochemical Pharmacology*, *58*(11), 1791–1799. [https://doi.org/10.1016/S0006-2952\(99\)00264-6](https://doi.org/10.1016/S0006-2952(99)00264-6)
- Bollinger, J. M., Kwon, D. S., Huisman, G. W., Kolter, R., & Walsh, C. T. (1995). Glutathionylspermidine Metabolism in *Escherichia coli*. *Journal of Biological Chemistry*, *270*(23), 14031–14041. <https://doi.org/10.1074/jbc.270.23.14031>
- Bond, C. S., Zhang, Y., Berriman, M., Cunningham, M. L., Fairlamb, A. H., & Hunter, W. N. (1999). Crystal structure of *Trypanosoma cruzi* trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. *Structure*, *7*(1), 81–89. [https://doi.org/10.1016/S0969-2126\(99\)80011-2](https://doi.org/10.1016/S0969-2126(99)80011-2)
- Brady, P. N., & Macnaughtan, M. A. (2015). Evaluation of colorimetric assays for analyzing reductively methylated proteins: Biases and mechanistic insights. *Analytical Biochemistry*, *491*, 43–51. <https://doi.org/10.1016/j.ab.2015.08.027>
- Braga, S. S. (2019). Multi-target drugs active against leishmaniasis: A paradigm of drug repurposing. *European Journal of Medicinal Chemistry*, *183*, 111660. <https://doi.org/10.1016/j.ejmech.2019.111660>
- Brígido, H. P. C., dos Santos, L. G. A., de Barros, R. C., Correa-Barbosa, J., Santos, P. V. B. dos, Paz, R. F. L., Pereira, A. R., Albuquerque, K. C. O. de, Campos, M. B., Silveira, F. T., Percário, S., & Dolabela, M. F. (2025). The Role of Oxidative Stress in the Pathogenesis and Treatment of Leishmaniasis: Impact on Drug Toxicity and Therapeutic Potential of Natural Products. *Toxics*, *13*(3), 190. <https://doi.org/10.3390/toxics13030190>
- Brindisi, M., Brogi, S., Relitti, N., Vallone, A., Butini, S., Gemma, S., Novellino, E., Colotti, G., Angiulli, G., Di Chiaro, F., Fiorillo, A., Ilari, A., & Campiani, G. (2015). Structure-based discovery of the first non-covalent inhibitors of *Leishmania major*

- tryparedoxin peroxidase by high throughput docking. *Scientific Reports*, 5(1), 9705. <https://doi.org/10.1038/srep09705>
- Bryant, J. M., Baumgarten, S., Glover, L., Hutchinson, S., & Rachidi, N. (2019). CRISPR in Parasitology: Not Exactly Cut and Dried! *Trends in Parasitology*, 35(6), 409–422. <https://doi.org/10.1016/j.pt.2019.03.004>
- Burza, S., Croft, S. L., & Boelaert, M. (2018). Leishmaniasis. *The Lancet*, 392(10151), 951–970. [https://doi.org/10.1016/S0140-6736\(18\)31204-2](https://doi.org/10.1016/S0140-6736(18)31204-2)
- Bussi, G., Donadio, D., & Parrinello, M. (2007). Canonical sampling through velocity rescaling. *The Journal of Chemical Physics*, 126(1). <https://doi.org/10.1063/1.2408420>
- Campos, R. A., da Silva, M. L., da Costa, G. V., Bisch, P. M., Peralta, J. M., Silva, R., Rondinelli, E., & Ürményi, T. P. (2012). Gene expression and molecular modeling of the HSP104 chaperone of *Trypanosoma cruzi*. *Genetics and Molecular Research*, 11(3), 2122–2129. <https://doi.org/10.4238/2012.August.6.15>
- Carneiro, M. B., Vaz, L. G., Afonso, L. C. C., Horta, M. F., & Vieira, L. Q. (2021). Regulation of macrophage subsets and cytokine production in leishmaniasis. *Cytokine*, 147, 155309. <https://doi.org/10.1016/j.cyto.2020.155309>
- Carvalho, L., Luque-Ortega, J. R., López-Martín, C., Castanys, S., Rivas, L., & Gamarro, F. (2011). The 8-Aminoquinoline Analogue Sitamaquine Causes Oxidative Stress in *Leishmania donovani* Promastigotes by Targeting Succinate Dehydrogenase. *Antimicrobial Agents and Chemotherapy*, 55(9), 4204–4210. <https://doi.org/10.1128/AAC.00520-11>
- Castro, H., Duarte, M., & Tomás, A. M. (2017). The Redox Metabolism and Oxidative Stress in *Leishmania* as a Crossroads for the Lethal Effect of Drugs. In *Drug Discovery for Leishmaniasis* (pp. 316–347). The Royal Society of Chemistry. <https://doi.org/10.1039/9781788010177-00316>
- Castro, H., & Tomás, A. M. (2008a). Peroxidases of Trypanosomatids. *Antioxidants & Redox Signaling*, 10(9), 1593–1606. <https://doi.org/10.1089/ars.2008.2050>
- Castro, H., & Tomás, A. M. (2008b). Peroxidases of Trypanosomatids. *Antioxidants & Redox Signaling*, 10(9), 1593–1606. <https://doi.org/10.1089/ars.2008.2050>
- Chagas, A. C., Oliveira, F., Debrabant, A., Valenzuela, J. G., Ribeiro, J. M. C., & Calvo, E. (2014). Lundep, a Sand Fly Salivary Endonuclease Increases *Leishmania* Parasite Survival in Neutrophils and Inhibits XIIa Contact Activation in Human Plasma. *PLoS Pathogens*, 10(2), e1003923. <https://doi.org/10.1371/journal.ppat.1003923>
- CHARLTON, R. L., ROSSI-BERGMANN, B., DENNY, P. W., & STEEL, P. G. (2018a). Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art. *Parasitology*, 145(2), 219–236. <https://doi.org/10.1017/S0031182017000993>

- CHARLTON, R. L., ROSSI-BERGMANN, B., DENNY, P. W., & STEEL, P. G. (2018b). Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art. *Parasitology*, 145(2), 219–236. <https://doi.org/10.1017/S0031182017000993>
- Chattopadhyay, A., & Jafurulla, Md. (2011). A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis. *Biochemical and Biophysical Research Communications*, 416(1–2), 7–12. <https://doi.org/10.1016/j.bbrc.2011.11.023>
- Chawla, B., & Madhubala, R. (2010). Drug targets in Leishmania. *Journal of Parasitic Diseases*, 34(1), 1–13. <https://doi.org/10.1007/s12639-010-0006-3>
- Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023). Macrophages in immunoregulation and therapeutics. *Signal Transduction and Targeted Therapy*, 8(1), 207. <https://doi.org/10.1038/s41392-023-01452-1>
- Chhajer, R., Bhattacharyya, A., & Ali, N. (2024). Cell Death in Leishmania donovani promastigotes in response to Mammalian Aurora Kinase B Inhibitor– Hesperadin. *Biomedicine & Pharmacotherapy*, 177, 116960. <https://doi.org/10.1016/j.biopha.2024.116960>
- Choi, H. L., Jain, S., Ruiz Postigo, J. A., Borisch, B., & Dagne, D. A. (2021). The global procurement landscape of leishmaniasis medicines. *PLOS Neglected Tropical Diseases*, 15(2), e0009181. <https://doi.org/10.1371/journal.pntd.0009181>
- Chowdhury, R., Mondal, D., Chowdhury, V., Faria, S., Alvar, J., Nabi, S. G., Boelaert, M., & Dash, A. P. (2014). How Far Are We from Visceral Leishmaniasis Elimination in Bangladesh? An Assessment of Epidemiological Surveillance Data. *PLoS Neglected Tropical Diseases*, 8(8), e3020. <https://doi.org/10.1371/journal.pntd.0003020>
- Chunge, C. N., Owate, J., Pamba, H. O., & Donno, L. (1990). Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 84(2), 221–225. [https://doi.org/10.1016/0035-9203\(90\)90263-E](https://doi.org/10.1016/0035-9203(90)90263-E)
- Collin, F. (2019). Chemical Basis of Reactive Oxygen Species Reactivity and Involvement in Neurodegenerative Diseases. *International Journal of Molecular Sciences*, 20(10), 2407. <https://doi.org/10.3390/ijms20102407>
- Colotti, G., Baiocco, P., Fiorillo, A., Boffi, A., Poser, E., Chiaro, F. Di, & Ilari, A. (2013). Structural Insights into the Enzymes of the Trypanothione Pathway: Targets for Antileishmaniasis Drugs. *Future Medicinal Chemistry*, 5(15), 1861–1875. <https://doi.org/10.4155/fmc.13.146>
- Colotti, G., Saccoliti, F., Gramiccia, M., Di Muccio, T., Prakash, J., Yadav, S., Dubey, V. K., Vistoli, G., Battista, T., Mocci, S., Fiorillo, A., Bibi, A., Madia, V. N., Messore, A., Costi, R., Di Santo, R., & Ilari, A. (2020). Structure-guided approach to identify a novel class of anti-leishmaniasis diaryl sulfide compounds targeting the

- trypanothione metabolism. *Amino Acids*, 52(2), 247–259. <https://doi.org/10.1007/s00726-019-02731-4>
- Comini, M. A., & Flohé, L. (2013). Trypanothione-Based Redox Metabolism of Trypanosomatids. In *Trypanosomatid Diseases* (pp. 167–199). Wiley. <https://doi.org/10.1002/9783527670383.ch9>
- Comini, M. A., Guerrero, S. A., Haile, S., Menge, U., Lünsdorf, H., & Flohé, L. (2004). Validation of Trypanosoma brucei trypanothione synthetase as drug target. *Free Radical Biology and Medicine*, 36(10), 1289–1302. <https://doi.org/10.1016/j.freeradbiomed.2004.02.008>
- Comini, M. A., Krauth-Siegel, R. L., & Bellanda, M. (2013a). Mono- and Dithiol Glutaredoxins in the Trypanothione-Based Redox Metabolism of Pathogenic Trypanosomes. *Antioxidants & Redox Signaling*, 19(7), 708–722. <https://doi.org/10.1089/ars.2012.4932>
- Comini, M. A., Krauth-Siegel, R. L., & Bellanda, M. (2013b). Mono- and Dithiol Glutaredoxins in the Trypanothione-Based Redox Metabolism of Pathogenic Trypanosomes. *Antioxidants & Redox Signaling*, 19(7), 708–722. <https://doi.org/10.1089/ars.2012.4932>
- Conceição-Silva, F., & Morgado, F. N. (2019). Leishmania Spp-Host Interaction: There Is Always an Onset, but Is There an End? *Frontiers in Cellular and Infection Microbiology*, 9. <https://doi.org/10.3389/fcimb.2019.00330>
- Courret, N., Fréhel, C., Gouhier, N., Pouchelet, M., Prina, E., Roux, P., & Antoine, J.-C. (2002). Biogenesis of *Leishmania* -harbouring parasitophorous vacuoles following phagocytosis of the metacyclic promastigote or amastigote stages of the parasites. *Journal of Cell Science*, 115(11), 2303–2316. <https://doi.org/10.1242/jcs.115.11.2303>
- Couto, N., Wood, J., & Barber, J. (2016). The role of glutathione reductase and related enzymes on cellular redox homeostasis network. *Free Radical Biology and Medicine*, 95, 27–42. <https://doi.org/10.1016/j.freeradbiomed.2016.02.028>
- Croft, S. L., Neal, R. A., Pendergast, W., & Chan, J. H. (1987). The activity of alkyl phosphorylcholines and related derivatives against *Leishmania donovani*. *Biochemical Pharmacology*, 36(16), 2633–2636. [https://doi.org/10.1016/0006-2952\(87\)90543-0](https://doi.org/10.1016/0006-2952(87)90543-0)
- Croft, S. L., Snowdon, D., & Yardley, V. (1996). The activities of four anticancer alkyllysophospholipids against *Leishmania donovani*, *Trypanosoma cruzi* and *Trypanosoma brucei*. *Journal of Antimicrobial Chemotherapy*, 38(6), 1041–1047. <https://doi.org/10.1093/jac/38.6.1041>
- Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006). Drug Resistance in Leishmaniasis. *Clinical Microbiology Reviews*, 19(1), 111–126. <https://doi.org/10.1128/CMR.19.1.111-126.2006>
- Cruz, A., & Beverley, S. M. (1990). Gene replacement in parasitic protozoa. *Nature*, 348(6297), 171–173. <https://doi.org/10.1038/348171a0>

- Csizmadia, F. (2000). JChem: Java Applets and Modules Supporting Chemical Database Handling from Web Browsers. *Journal of Chemical Information and Computer Sciences*, 40(2), 323–324. <https://doi.org/10.1021/ci9902696>
- Cunningham, M. L., & Fairlamb, A. H. (1995). Trypanothione Reductase from *Leishmania donovani*. Purification, Characterisation and Inhibition by Trivalent Antimonials. *European Journal of Biochemistry*, 230(2), 460–468. <https://doi.org/10.1111/j.1432-1033.1995.tb20583.x>
- da Silva, A. D., dos Santos, J. A., Machado, P. A., Alves, L. A., Laque, L. C., de Souza, V. C., Coimbra, E. S., & Capriles, P. V. S. Z. (2019). Insights about resveratrol analogs against trypanothione reductase of *Leishmania braziliensis*: Molecular modeling, computational docking and *in vitro* antileishmanial studies. *Journal of Biomolecular Structure and Dynamics*, 37(11), 2960–2969. <https://doi.org/10.1080/07391102.2018.1502096>
- Dallakyan, S., & Olson, A. J. (2015). *Small-Molecule Library Screening by Docking with PyRx* (pp. 243–250). https://doi.org/10.1007/978-1-4939-2269-7_19
- Das, P., Saha, S., & BoseDasgupta, S. (2021). The ultimate fate determinants of drug induced cell-death mechanisms in Trypanosomatids. *International Journal for Parasitology: Drugs and Drug Resistance*, 15, 81–91. <https://doi.org/10.1016/j.ijpddr.2021.01.003>
- Das, V. N., Ranjan, A., Sinha, A. N., Verma, N., Lal, C. S., Gupta, A. K., Siddiqui, N. A., & Kar, S. K. (2001). A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. *The Journal of the Association of Physicians of India*, 49, 609–613.
- de Molfetta, F. A., de Freitas, R. F., da Silva, A. B. F., & Montanari, C. A. (2009). Docking and molecular dynamics simulation of quinone compounds with trypanocidal activity. *Journal of Molecular Modeling*, 15(10), 1175–1184. <https://doi.org/10.1007/s00894-009-0468-3>
- De Muylder, G., Daulouède, S., Lecordier, L., Uzureau, P., Morias, Y., Van Den Abbeele, J., Caljon, G., Hérin, M., Holzmüller, P., Semballa, S., Courtois, P., Vanhamme, L., Stijlemans, B., De Baetselier, P., Barrett, M. P., Barlow, J. L., McKenzie, A. N. J., Barron, L., Wynn, T. A., ... Pays, E. (2013). A Trypanosoma brucei Kinesin Heavy Chain Promotes Parasite Growth by Triggering Host Arginase Activity. *PLoS Pathogens*, 9(10), e1003731. <https://doi.org/10.1371/journal.ppat.1003731>
- Decuypere, S., Vanaerschot, M., Brunker, K., Imamura, H., Müller, S., Khanal, B., Rijal, S., Dujardin, J.-C., & Coombs, G. H. (2012). Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background. *PLoS Neglected Tropical Diseases*, 6(2), e1514. <https://doi.org/10.1371/journal.pntd.0001514>

- Dhiman, R. C. (2014). Emerging Vector-Borne Zoonoses: Eco-Epidemiology and Public Health Implications in India. *Frontiers in Public Health*, 2. <https://doi.org/10.3389/fpubh.2014.00168>
- Didier, A. J., Stiene, J., Fang, L., Watkins, D., Dworkin, L. D., & Creeden, J. F. (2023). Antioxidant and Anti-Tumor Effects of Dietary Vitamins A, C, and E. *Antioxidants*, 12(3), 632. <https://doi.org/10.3390/antiox12030632>
- Diesen, D. L., & Kuo, P. C. (2010). Nitric Oxide and Redox Regulation in the Liver: Part I. General Considerations and Redox Biology in Hepatitis. *Journal of Surgical Research*, 162(1), 95–109. <https://doi.org/10.1016/j.jss.2009.09.019>
- Dietze, R., Carvalho, S. F., Valli, L. C., Berman, J., Brewer, T., Milhous, W., Sanchez, J., Schuster, B., & Grogl, M. (2001). Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by *Leishmania chagasi*. *The American Journal of Tropical Medicine and Hygiene*, 65(6), 685–689. <https://doi.org/10.4269/ajtmh.2001.65.685>
- Dinc, R. (2022). Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future. *The Korean Journal of Parasitology*, 60(6), 379–391. <https://doi.org/10.3347/kjp.2022.60.6.379>
- Dinescu, A., Brown, T. R., Barelier, S., Cundari, T. R., & Anderson, M. E. (2010). The role of the glycine triad in human glutathione synthetase. *Biochemical and Biophysical Research Communications*, 400(4), 511–516. <https://doi.org/10.1016/j.bbrc.2010.08.081>
- Dinesh, N., Kaur, P. K., Swamy, K. K., & Singh, S. (2014). Mianserin, an antidepressant kills *Leishmania donovani* by depleting ergosterol levels. *Experimental Parasitology*, 144, 84–90. <https://doi.org/10.1016/j.exppara.2014.06.004>
- Dolai, S., & Adak, S. (2014). Endoplasmic reticulum stress responses in *Leishmania*. *Molecular and Biochemical Parasitology*, 197(1–2), 1–8. <https://doi.org/10.1016/j.molbiopara.2014.09.002>
- Dolai, S., Yadav, R. K., Pal, S., & Adak, S. (2008). *Leishmania* major ascorbate peroxidase overexpression protects cells against reactive oxygen species-mediated cardiolipin oxidation. *Free Radical Biology and Medicine*, 45(11), 1520–1529. <https://doi.org/10.1016/j.freeradbiomed.2008.08.029>
- Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012). Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. *Journal of Antimicrobial Chemotherapy*, 67(11), 2576–2597. <https://doi.org/10.1093/jac/dks275>
- Downing, T., Imamura, H., Decuypere, S., Clark, T. G., Coombs, G. H., Cotton, J. A., Hilley, J. D., de Doncker, S., Maes, I., Mottram, J. C., Quail, M. A., Rijal, S., Sanders, M., Schönian, G., Stark, O., Sundar, S., Vanaerschot, M., Hertz-Fowler, C., Dujardin, J.-C., & Berriman, M. (2011a). Whole genome sequencing of multiple *Leishmania donovani* clinical isolates provides insights into population structure

- and mechanisms of drug resistance. *Genome Research*, 21(12), 2143–2156. <https://doi.org/10.1101/gr.123430.111>
- Downing, T., Imamura, H., Decuypere, S., Clark, T. G., Coombs, G. H., Cotton, J. A., Hilley, J. D., de Doncker, S., Maes, I., Mottram, J. C., Quail, M. A., Rijal, S., Sanders, M., Schönian, G., Stark, O., Sundar, S., Vanaerschot, M., Hertz-Fowler, C., Dujardin, J.-C., & Berriman, M. (2011b). Whole genome sequencing of multiple *Leishmania donovani* clinical isolates provides insights into population structure and mechanisms of drug resistance. *Genome Research*, 21(12), 2143–2156. <https://doi.org/10.1101/gr.123430.111>
- Dumas, C. (1997). Disruption of the trypanothione reductase gene of *Leishmania* decreases its ability to survive oxidative stress in macrophages. *The EMBO Journal*, 16(10), 2590–2598. <https://doi.org/10.1093/emboj/16.10.2590>
- Dumetz, F., Imamura, H., Sanders, M., Seblova, V., Myskova, J., Pescher, P., Vanaerschot, M., Meehan, C. J., Cuypers, B., De Muylder, G., Späth, G. F., Bussotti, G., Vermeesch, J. R., Berriman, M., Cotton, J. A., Volf, P., Dujardin, J. C., & Domagalska, M. A. (2017a). Modulation of Aneuploidy in *Leishmania donovani* during Adaptation to Different *In Vitro* and *In Vivo* Environments and Its Impact on Gene Expression. *MBio*, 8(3). <https://doi.org/10.1128/mBio.00599-17>
- Dumetz, F., Imamura, H., Sanders, M., Seblova, V., Myskova, J., Pescher, P., Vanaerschot, M., Meehan, C. J., Cuypers, B., De Muylder, G., Späth, G. F., Bussotti, G., Vermeesch, J. R., Berriman, M., Cotton, J. A., Volf, P., Dujardin, J. C., & Domagalska, M. A. (2017b). Modulation of Aneuploidy in *Leishmania donovani* during Adaptation to Different *In Vitro* and *In Vivo* Environments and Its Impact on Gene Expression. *MBio*, 8(3). <https://doi.org/10.1128/mBio.00599-17>
- Dummer, R., Krasovec, M., Röger, J., Sindermann, H., & Burg, G. (1993). Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: Results of a phase I/II study. *Journal of the American Academy of Dermatology*, 29(6), 963–970. [https://doi.org/10.1016/0190-9622\(93\)70275-X](https://doi.org/10.1016/0190-9622(93)70275-X)
- El-Sayed, N. M., Myler, P. J., Bartholomeu, D. C., Nilsson, D., Aggarwal, G., Tran, A.-N., Ghedin, E., Worthey, E. A., Delcher, A. L., Blandin, G., Westenberger, S. J., Caler, E., Cerqueira, G. C., Branche, C., Haas, B., Anupama, A., Arner, E., Åslund, L., Attipoe, P., ... Andersson, B. (2005). The Genome Sequence of *Trypanosoma cruzi*, Etiologic Agent of Chagas Disease. *Science*, 309(5733), 409–415. <https://doi.org/10.1126/science.1112631>
- Engstler, M., & Beneke, T. (2023a). Gene editing and scalable functional genomic screening in *Leishmania* species using the CRISPR/Cas9 cytosine base editor toolbox LeishBASEedit. *ELife*, 12. <https://doi.org/10.7554/eLife.85605>
- Engstler, M., & Beneke, T. (2023b). Gene editing and scalable functional genomic screening in *Leishmania* species using the CRISPR/Cas9 cytosine base editor toolbox LeishBASEedit. *ELife*, 12. <https://doi.org/10.7554/eLife.85605>
- Eqbal, A., Suman, S. S., Anwar, S., Singh, K. P., Zaidi, A., Sardar, A. H., Das, P., & Ali, V. (2014). Stage-Dependent Expression and Up-Regulation of Trypanothione

- Synthetase in Amphotericin B Resistant *Leishmania donovani*. *PLoS ONE*, 9(6), e97600. <https://doi.org/10.1371/journal.pone.0097600>
- Escrivani, D. O., Charlton, R. L., Caruso, M. B., Burle-Caldas, G. A., Borsodi, M. P. G., Zingali, R. B., Arruda-Costa, N., Palmeira-Mello, M. V., de Jesus, J. B., Souza, A. M. T., Abrahim-Vieira, B., Freitag-Pohl, S., Pohl, E., Denny, P. W., Rossi-Bergmann, B., & Steel, P. G. (2021). Chalcones identify cTXNPx as a potential antileishmanial drug target. *PLOS Neglected Tropical Diseases*, 15(11), e0009951. <https://doi.org/10.1371/journal.pntd.0009951>
- Espada, C. R., Quilles, J. C., Albuquerque-Wendt, A., Cruz, M. C., Beneke, T., Lorenzon, L. B., Gluenz, E., Cruz, A. K., & Uliana, S. R. B. (2021a). Effective Genome Editing in *Leishmania (Viannia) braziliensis* Stably Expressing Cas9 and T7 RNA Polymerase. *Frontiers in Cellular and Infection Microbiology*, 11. <https://doi.org/10.3389/fcimb.2021.772311>
- Espada, C. R., Quilles, J. C., Albuquerque-Wendt, A., Cruz, M. C., Beneke, T., Lorenzon, L. B., Gluenz, E., Cruz, A. K., & Uliana, S. R. B. (2021b). Effective Genome Editing in *Leishmania (Viannia) braziliensis* Stably Expressing Cas9 and T7 RNA Polymerase. *Frontiers in Cellular and Infection Microbiology*, 11. <https://doi.org/10.3389/fcimb.2021.772311>
- Faerman, C. H., Savvides, S. N., Strickland, C., Breidenbach, M. A., Ponasik, J. A., Ganem, B., Ripoll, D., Luise Krauth-Siegel, R., & Andrew Karplus, P. (1996). Charge is the major discriminating factor for glutathione reductase versus trypanothione reductase inhibitors. *Bioorganic & Medicinal Chemistry*, 4(8), 1247–1253. [https://doi.org/10.1016/0968-0896\(96\)00120-4](https://doi.org/10.1016/0968-0896(96)00120-4)
- Fairlamb, A. H., Blackburn, P., Ulrich, P., Chait, B. T., & Cerami, A. (1985a). Trypanothione: A Novel Bis(glutathionyl)spermidine Cofactor for Glutathione Reductase in Trypanosomatids. *Science*, 227(4693), 1485–1487. <https://doi.org/10.1126/science.3883489>
- Fairlamb, A. H., Blackburn, P., Ulrich, P., Chait, B. T., & Cerami, A. (1985b). Trypanothione: A Novel Bis(glutathionyl)spermidine Cofactor for Glutathione Reductase in Trypanosomatids. *Science*, 227(4693), 1485–1487. <https://doi.org/10.1126/science.3883489>
- Fairlamb, A. H., & Cerami, A. (1992). METABOLISM AND FUNCTIONS OF TRYpanOTHIONE IN THE KINETOPLASTIDA. *Annual Review of Microbiology*, 46(1), 695–729. <https://doi.org/10.1146/annurev.mi.46.100192.003403>
- Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A., & Corn, J. E. (2017). Cornerstones of CRISPR–Cas in drug discovery and therapy. *Nature Reviews Drug Discovery*, 16(2), 89–100. <https://doi.org/10.1038/nrd.2016.238>
- Flohé, L. (2012). The trypanothione system and the opportunities it offers to create drugs for the neglected kinetoplast diseases. *Biotechnology Advances*, 30(1), 294–301. <https://doi.org/10.1016/j.biotechadv.2011.05.012>

- Forman, H. J., & Zhang, H. (2021). Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. *Nature Reviews Drug Discovery*, 20(9), 689–709. <https://doi.org/10.1038/s41573-021-00233-1>
- Forman, H. J., Zhang, H., & Rinna, A. (2009). Glutathione: Overview of its protective roles, measurement, and biosynthesis. *Molecular Aspects of Medicine*, 30(1–2), 1–12. <https://doi.org/10.1016/j.mam.2008.08.006>
- Freitas, C. S., Lage, D. P., Machado, A. S., Vale, D. L., Martins, V. T., Cardoso, J. M. O., Oliveira-da-Silva, J. A., Reis, T. A. R., Tavares, G. S. V., Ramos, F. F., Ludolf, F., Pereira, I. A. G., Bandeira, R. S., Fujiwara, R. T., Bueno, L. L., Roatt, B. M., Chávez-Fumagalli, M. A., & Coelho, E. A. F. (2023). Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasis. *Cytokine*, 164, 156143. <https://doi.org/10.1016/j.cyto.2023.156143>
- Frézard, F., Aguiar, M. M. G., Ferreira, L. A. M., Ramos, G. S., Santos, T. T., Borges, G. S. M., Vallejos, V. M. R., & De Moraes, H. L. O. (2022). Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations. *Pharmaceutics*, 15(1), 99. <https://doi.org/10.3390/pharmaceutics15010099>
- Friedrich, N.-O., de Bruyn Kops, C., Flachsenberg, F., Sommer, K., Rarey, M., & Kirchmair, J. (2017). Benchmarking Commercial Conformer Ensemble Generators. *Journal of Chemical Information and Modeling*, 57(11), 2719–2728. <https://doi.org/10.1021/acs.jcim.7b00505>
- Fulda, S. (2016). Regulation of necroptosis signaling and cell death by reactive oxygen species. *Biological Chemistry*, 397(7), 657–660. <https://doi.org/10.1515/hsz-2016-0102>
- Fyfe, P. K., Oza, S. L., Fairlamb, A. H., & Hunter, W. N. (2008). Leishmania Trypanothione Synthetase-Amidase Structure Reveals a Basis for Regulation of Conflicting Synthetic and Hydrolytic Activities. *Journal of Biological Chemistry*, 283(25), 17672–17680. <https://doi.org/10.1074/jbc.M801850200>
- García-Caparrós, P., De Filippis, L., Gul, A., Hasanuzzaman, M., Ozturk, M., Altay, V., & Lao, M. T. (2021). Oxidative Stress and Antioxidant Metabolism under Adverse Environmental Conditions: a Review. *The Botanical Review*, 87(4), 421–466. <https://doi.org/10.1007/s12229-020-09231-1>
- Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. *Expert Opinion on Drug Discovery*, 10(5), 449–461. <https://doi.org/10.1517/17460441.2015.1032936>
- Ghisla, S., & Massey, V. (1989). Mechanisms of flavoprotein-catalyzed reactions. In *EJB Reviews 1989* (pp. 29–45). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-75189-9_3

- Ghorai, S. (2023). Editorial: Reviews in neglected tropical infectious diseases. *Frontiers in Microbiology*, 14. <https://doi.org/10.3389/fmicb.2023.1196838>
- Ghosh, A. P., & Roth, K. A. (2014). Detection of Apoptosis and Autophagy. In *Pathobiology of Human Disease* (pp. 3841–3858). Elsevier. <https://doi.org/10.1016/B978-0-12-386456-7.07406-2>
- Giraud, E., Martin, O., Yakob, L., & Rogers, M. (2019). Quantifying Leishmania Metacyclic Promastigotes from Individual Sandfly Bites Reveals the Efficiency of Vector Transmission. *Communications Biology*, 2(1), 84. <https://doi.org/10.1038/s42003-019-0323-8>
- González-Chávez, Z., Vázquez, C., Mejía-Tlachi, M., Márquez-Dueñas, C., Manning-Cela, R., Encalada, R., Rodríguez-Enríquez, S., Michels, P. A. M., Moreno-Sánchez, R., & Saavedra, E. (2019). Gamma-glutamylcysteine synthetase and tryparedoxin 1 exert high control on the antioxidant system in Trypanosoma cruzi contributing to drug resistance and infectivity. *Redox Biology*, 26, 101231. <https://doi.org/10.1016/j.redox.2019.101231>
- González-Montero, M.-C., Andrés-Rodríguez, J., García-Fernández, N., Pérez-Pertejo, Y., Reguera, R. M., Balaña-Fouce, R., & García-Estrada, C. (2024). Targeting Trypanothione Metabolism in Trypanosomatids. *Molecules*, 29(10), 2214. <https://doi.org/10.3390/molecules29102214>
- Goswami, R. P., Rahman, M., Das, S., Tripathi, S. K., & Goswami, R. P. (2020). Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome™) and Short-Course Miltefosine in Comparison to Miltefosine Monotherapy. *The American Journal of Tropical Medicine and Hygiene*, 103(1), 308–314. <https://doi.org/10.4269/ajtmh.19-0931>
- Goto, Y. (2025). Immunomodulation by Leishmania parasites: Potential for controlling other diseases. *Parasitology International*, 104, 102987. <https://doi.org/10.1016/j.parint.2024.102987>
- Grant, C. M., MacIver, F. H., & Dawes, I. W. (1997). Glutathione synthetase is dispensable for growth under both normal and oxidative stress conditions in the yeast *Saccharomyces cerevisiae* due to an accumulation of the dipeptide gamma-glutamylcysteine. *Molecular Biology of the Cell*, 8(9), 1699–1707. <https://doi.org/10.1091/mbc.8.9.1699>
- Green, D. R., & Kroemer, G. (2004). The Pathophysiology of Mitochondrial Cell Death. *Science*, 305(5684), 626–629. <https://doi.org/10.1126/science.1099320>
- Griffith, O. W. (1999). Biologic and pharmacologic regulation of mammalian glutathione synthesis. *Free Radical Biology and Medicine*, 27(9–10), 922–935. [https://doi.org/10.1016/S0891-5849\(99\)00176-8](https://doi.org/10.1016/S0891-5849(99)00176-8)
- Guimarães-Costa, A. B., DeSouza-Vieira, T. S., Paletta-Silva, R., Freitas-Mesquita, A. L., Meyer-Fernandes, J. R., & Saraiva, E. M. (2014). 3'-Nucleotidase/Nuclease Activity Allows Leishmania Parasites To Escape Killing by Neutrophil Extracellular

- Traps. *Infection and Immunity*, 82(4), 1732–1740. <https://doi.org/10.1128/IAI.01232-13>
- Haimeur, A., Brochu, C., Genest, P.-A., Papadopoulou, B., & Ouellette, M. (2000). Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant *Leishmania tarentolae*. *Molecular and Biochemical Parasitology*, 108(1), 131–135. [https://doi.org/10.1016/S0166-6851\(00\)00187-0](https://doi.org/10.1016/S0166-6851(00)00187-0)
- Hallé, M., Gomez, M. A., Stuiblé, M., Shimizu, H., McMaster, W. R., Olivier, M., & Tremblay, M. L. (2009). The *Leishmania* Surface Protease GP63 Cleaves Multiple Intracellular Proteins and Actively Participates in p38 Mitogen-activated Protein Kinase Inactivation. *Journal of Biological Chemistry*, 284(11), 6893–6908. <https://doi.org/10.1074/jbc.M805861200>
- Halliday, C., de Liz, L. V., Vaughan, S., & Sunter, J. D. (2024). Disruption of *Leishmania* flagellum attachment zone architecture causes flagellum loss. *Molecular Microbiology*, 121(1), 53–68. <https://doi.org/10.1111/mmi.15199>
- Hamid, A., Mäser, P., & Mahmoud, A. B. (2024). Drug Repurposing in the Chemotherapy of Infectious Diseases. *Molecules*, 29(3), 635. <https://doi.org/10.3390/molecules29030635>
- Hazra, S., Ghosh, S., Sarma, M. Das, Sharma, S., Das, M., Saudagar, P., Prajapati, V. K., Dubey, V. K., Sundar, S., & Hazra, B. (2013). Evaluation of a diospyrin derivative as antileishmanial agent and potential modulator of ornithine decarboxylase of *Leishmania donovani*. *Experimental Parasitology*, 135(2), 407–413. <https://doi.org/10.1016/j.exppara.2013.07.021>
- Henard, C. A., Carlsen, E. D., Hay, C., Kima, P. E., & Soong, L. (2014). *Leishmania amazonensis* Amastigotes Highly Express a Tryparedoxin Peroxidase Isoform That Increases Parasite Resistance to Macrophage Antimicrobial Defenses and Fosters Parasite Virulence. *PLoS Neglected Tropical Diseases*, 8(7), e3000. <https://doi.org/10.1371/journal.pntd.0003000>
- Henderson, G. B., Fairlamb, A. H., & Cerami, A. (1987). Trypanothione dependent peroxide metabolism in *Crithidia fasciculata* and *Trypanosoma brucei*. *Molecular and Biochemical Parasitology*, 24(1), 39–45. [https://doi.org/10.1016/0166-6851\(87\)90113-7](https://doi.org/10.1016/0166-6851(87)90113-7)
- Heo, L., Park, H., & Seok, C. (2013). GalaxyRefine: protein structure refinement driven by side-chain repacking. *Nucleic Acids Research*, 41(W1), W384–W388. <https://doi.org/10.1093/nar/gkt458>
- Hermoso, T., Fishelson, Z., Becker, S. I., Hirschberg, K., & Jaffe, C. L. (1991). Leishmanial protein kinases phosphorylate components of the complement system. *The EMBO Journal*, 10(13), 4061–4067. <https://doi.org/10.1002/j.1460-2075.1991.tb04982.x>
- Hiller, C., Nissen, A., Benítez, D., Comini, M. A., & Krauth-Siegel, R. L. (2014). Cytosolic Peroxidases Protect the Lysosome of Bloodstream African

- Trypanosomes from Iron-Mediated Membrane Damage. *PLoS Pathogens*, 10(4), e1004075. <https://doi.org/10.1371/journal.ppat.1004075>
- Hsu, J.-Y., Lin, Y.-C., Chiang, S.-C., & Lee, S. T. (2008). Divergence of trypanothione-dependent tryparedoxin cascade into cytosolic and mitochondrial pathways in arsenite-resistant variants of *Leishmania amazonensis*. *Molecular and Biochemical Parasitology*, 157(2), 193–204. <https://doi.org/10.1016/j.molbiopara.2007.11.002>
- Huang, M., Zhang, W., Chen, H., & Zeng, J. (2020). Targeting Polyamine Metabolism for Control of Human Viral Diseases. *Infection and Drug Resistance*, Volume 13, 4335–4346. <https://doi.org/10.2147/IDR.S262024>
- Huggins, D. J., Sherman, W., & Tidor, B. (2012). Rational Approaches to Improving Selectivity in Drug Design. *Journal of Medicinal Chemistry*, 55(4), 1424–1444. <https://doi.org/10.1021/jm2010332>
- Huynh, T. T., Huynh, V. T., Harmon, M. A., & Phillips, M. A. (2003). Gene Knockdown of γ -Glutamylcysteine Synthetase by RNAi in the Parasitic Protozoa *Trypanosoma brucei* Demonstrates That It Is an Essential Enzyme. *Journal of Biological Chemistry*, 278(41), 39794–39800. <https://doi.org/10.1074/jbc.M306306200>
- Hwang, H.-Y., Gilberts, T., Jardim, A., Shih, S., & Ullman, B. (1996). Creation of Homozygous Mutants of *Leishmania donovani* with Single Targeting Constructs. *Journal of Biological Chemistry*, 271(48), 30840–30846. <https://doi.org/10.1074/jbc.271.48.30840>
- Ilaghi, M., Sharifi, I., Sharififar, F., Sharifi, F., Oliaee, R. T., Babaei, Z., Meimamandi, M. S., Keyhani, A., & Bamorovat, M. (2021). The potential role and apoptotic profile of three medicinal plant extracts on *Leishmania tropica* by MTT assay, macrophage model and flow cytometry analysis. *Parasite Epidemiology and Control*, 12, e00201. <https://doi.org/10.1016/j.parepi.2021.e00201>
- Ilari, A., Fiorillo, A., Genovese, I., & Colotti, G. (2017). Polyamine-Trypanothione Pathway: An Update. *Future Medicinal Chemistry*, 9(1), 61–77. <https://doi.org/10.4155/fmc-2016-0180>
- Irigoín, F., Cibils, L., Comini, M. A., Wilkinson, S. R., Flohé, L., & Radi, R. (2008). Insights into the redox biology of *Trypanosoma cruzi*: Trypanothione metabolism and oxidant detoxification. *Free Radical Biology and Medicine*, 45(6), 733–742. <https://doi.org/10.1016/j.freeradbiomed.2008.05.028>
- Islamuddin, M., Ali, A., Afzal, O., Ali, A., Ali, I., Altamimi, A. S. A., Alamri, M. A., Kato, K., & Parveen, S. (2022). Thymoquinone Induced Leishmanicidal Effect via Programmed Cell Death in *Leishmania donovani*. *ACS Omega*, 7(12), 10718–10728. <https://doi.org/10.1021/acsomega.2c00467>
- Ivens, A. C., Peacock, C. S., Worthey, E. A., Murphy, L., Aggarwal, G., Berriman, M., Sisk, E., Rajandream, M.-A., Adlem, E., Aert, R., Anupama, A., Apostolou, Z., Attipoe, P., Bason, N., Bauser, C., Beck, A., Beverley, S. M., Bianchetti, G.,

- Borzym, K., ... Myler, P. J. (2005). The Genome of the Kinetoplastid Parasite, *Leishmania major*. *Science*, 309(5733), 436–442. <https://doi.org/10.1126/science.1112680>
- Iyer, J. P., Kaprakkaden, A., Choudhary, M. L., & Shaha, C. (2008). Crucial role of cytosolic trypanothione peroxidase in *Leishmania donovani* survival, drug response and virulence. *Molecular Microbiology*, 68(2), 372–391. <https://doi.org/10.1111/j.1365-2958.2008.06154.x>
- Jha, T. K., Giri, Y. N., Singh, T. K., & Jha, S. (1995). Use of Amphotericin B in Drug-Resistant Cases of Visceral Leishmaniasis in North Bihar, India. *The American Journal of Tropical Medicine and Hygiene*, 52(6), 536–538. <https://doi.org/10.4269/ajtmh.1995.52.536>
- Jha, T. K., Sundar, S., Thakur, C. P., Felton, J. M., Sabin, A. J., & Horton, J. (2005). A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. *The American Journal of Tropical Medicine and Hygiene*, 73(6), 1005–1011.
- Jin, G., & Wong, S. T. C. (2014). Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. *Drug Discovery Today*, 19(5), 637–644. <https://doi.org/10.1016/j.drudis.2013.11.005>
- JOCKERS-SCHERÜBL, M. C., SCHIRMER, R. H., & KRAUTH-SIEGEL, R. L. (1989). Trypanothione reductase from *Trypanosoma cruzi*. *European Journal of Biochemistry*, 180(2), 267–272. <https://doi.org/10.1111/j.1432-1033.1989.tb14643.x>
- Joerger, M., Hartmann, K., & Kuhn, M. (2009). *Drugs acting on the respiratory tract* (pp. 305–319). [https://doi.org/10.1016/S0378-6080\(09\)03116-X](https://doi.org/10.1016/S0378-6080(09)03116-X)
- Jones, N. G., Catta-Preta, C. M. C., Lima, A. P. C. A., & Mottram, J. C. (2018). Genetically Validated Drug Targets in *Leishmania*: Current Knowledge and Future Prospects. *ACS Infectious Diseases*, 4(4), 467–477. <https://doi.org/10.1021/acsinfecdis.7b00244>
- Joo, K., Lee, J., Seo, J., Lee, K., Kim, B., & Lee, J. (2009). All-atom chain-building by optimizing MODELLER energy function using conformational space annealing. *Proteins: Structure, Function, and Bioinformatics*, 75(4), 1010–1023. <https://doi.org/10.1002/prot.22312>
- Kajstura, M., Halicka, H. D., Pryjma, J., & Darzynkiewicz, Z. (2007a). Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete “sub-G₁” peaks on DNA content histograms. *Cytometry Part A*, 71A(3), 125–131. <https://doi.org/10.1002/cyto.a.20357>
- Kajstura, M., Halicka, H. D., Pryjma, J., & Darzynkiewicz, Z. (2007b). Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete “sub-G₁” peaks on DNA content histograms. *Cytometry Part A*, 71A(3), 125–131. <https://doi.org/10.1002/cyto.a.20357>

- Kawata, M., & Nagashima, U. (2001). Particle mesh Ewald method for three-dimensional systems with two-dimensional periodicity. *Chemical Physics Letters*, 340(1–2), 165–172. [https://doi.org/10.1016/S0009-2614\(01\)00393-1](https://doi.org/10.1016/S0009-2614(01)00393-1)
- Kennedy, A. D., & DeLeo, F. R. (2009). Neutrophil apoptosis and the resolution of infection. *Immunologic Research*, 43(1–3), 25–61. <https://doi.org/10.1007/s12026-008-8049-6>
- Khan, M. O., Austin, S. E., Chan, C., Yin, H., Marks, D., Vaghjiani, S. N., Kendrick, H., Yardley, V., Croft, S. L., & Douglas, K. T. (2000). Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines. *Journal of Medicinal Chemistry*, 43(16), 3148–3156. <https://doi.org/10.1021/jm000156+>
- Khanra, S., Datta, S., Mondal, D., Saha, P., Bandopadhyay, S. K., Roy, S., & Manna, M. (2012). RFLPs of ITS, ITS1 and hsp70 amplicons and sequencing of ITS1 of recent clinical isolates of Kala-azar from India and Bangladesh confirms the association of *L. tropica* with the disease. *Acta Tropica*, 124(3), 229–234. <https://doi.org/10.1016/j.actatropica.2012.08.017>
- Kitazumi, I., & Tsukahara, M. (2011). Regulation of DNA fragmentation: the role of caspases and phosphorylation. *The FEBS Journal*, 278(3), 427–441. <https://doi.org/10.1111/j.1742-4658.2010.07975.x>
- Ko, J., Park, H., & Seok, C. (2012). GalaxyTBM: template-based modeling by building a reliable core and refining unreliable local regions. *BMC Bioinformatics*, 13(1), 198. <https://doi.org/10.1186/1471-2105-13-198>
- Koch, O., Cappel, D., Nocker, M., Jäger, T., Flohé, L., Sotriffer, C. A., & Selzer, P. M. (2013). Molecular Dynamics Reveal Binding Mode of Glutathionylspermidine by Trypanothione Synthetase. *PLoS ONE*, 8(2), e56788. <https://doi.org/10.1371/journal.pone.0056788>
- Krauth-Siegel, R. L., Bauer, H., & Schirmer, R. H. (2005). Dithiol Proteins as Guardians of the Intracellular Redox Milieu in Parasites: Old and New Drug Targets in Trypanosomes and Malaria-Causing Plasmodia. *Angewandte Chemie International Edition*, 44(5), 690–715. <https://doi.org/10.1002/anie.200300639>
- Krauth-Siegel, R. L., & Comini, M. A. (2008a). Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1780(11), 1236–1248. <https://doi.org/10.1016/j.bbagen.2008.03.006>
- Krauth-Siegel, R. L., & Comini, M. A. (2008b). Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1780(11), 1236–1248. <https://doi.org/10.1016/j.bbagen.2008.03.006>
- KRAUTH-SIEGEL, R. L., ENDERS, B., HENDERSON, G. B., FAIRLAMB, A. H., & SCHIRMER, R. H. (1987). Trypanothione reductase from *Trypanosoma cruzi*.

- Purification and characterization of the crystalline enzyme. *European Journal of Biochemistry*, 164(1), 123–128. <https://doi.org/10.1111/j.1432-1033.1987.tb11002.x>
- Krauth-Siegel, R. L., & Leroux, A. E. (2012). Low-Molecular-Mass Antioxidants in Parasites. *Antioxidants & Redox Signaling*, 17(4), 583–607. <https://doi.org/10.1089/ars.2011.4392>
- Krayter, L., Bumb, R. A., Azmi, K., Wuttke, J., Malik, M. D., Schnur, L. F., Salotra, P., & Schönian, G. (2014). Multilocus microsatellite typing reveals a genetic relationship but, also, genetic differences between Indian strains of *Leishmania tropica* causing cutaneous leishmaniasis and those causing visceral leishmaniasis. *Parasites & Vectors*, 7(1), 123. <https://doi.org/10.1186/1756-3305-7-123>
- Krieger, S., Schwarz, W., Ariyanayagam, M. R., Fairlamb, A. H., Krauth-Siegel, R. L., & Clayton, C. (2000). Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. *Molecular Microbiology*, 35(3), 542–552. <https://doi.org/10.1046/j.1365-2958.2000.01721.x>
- Kuhlencord, A., Maniera, T., Eibl, H., & Unger, C. (1992). Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. *Antimicrobial Agents and Chemotherapy*, 36(8), 1630–1634. <https://doi.org/10.1128/AAC.36.8.1630>
- Kuldeep, J., R., K., Kaur, P., Goyal, N., & Siddiqi, M. I. (2021). Identification of potential anti-leishmanial agents using computational investigation and biological evaluation against trypanothione reductase. *Journal of Biomolecular Structure and Dynamics*, 39(3), 960–969. <https://doi.org/10.1080/07391102.2020.1721330>
- Kumar, A., Chauhan, N., & Singh, S. (2019a). Understanding the Cross-Talk of Redox Metabolism and Fe-S Cluster Biogenesis in *Leishmania* Through Systems Biology Approach. *Frontiers in Cellular and Infection Microbiology*, 9. <https://doi.org/10.3389/fcimb.2019.00015>
- Kumar, A., Chauhan, N., & Singh, S. (2019b). Understanding the Cross-Talk of Redox Metabolism and Fe-S Cluster Biogenesis in *Leishmania* Through Systems Biology Approach. *Frontiers in Cellular and Infection Microbiology*, 9. <https://doi.org/10.3389/fcimb.2019.00015>
- Kumar, V., Ghosh, S., Roy, K., Pal, C., & Singh, S. (2021). Deletion of Glutamine Synthetase Gene Disrupts the Survivability and Infectivity of *Leishmania donovani*. *Frontiers in Cellular and Infection Microbiology*, 11. <https://doi.org/10.3389/fcimb.2021.622266>
- Kundu, D., & Dubey, V. K. (2021). Potential alternatives to current cholinesterase inhibitors: an *in silico* drug repurposing approach. *Drug Development and Industrial Pharmacy*, 47(6), 919–930. <https://doi.org/10.1080/03639045.2021.1952216>
- Laffitte, M.-C. N., Leprohon, P., Papadopoulou, B., & Ouellette, M. (2016). Plasticity of the *Leishmania* genome leading to gene copy number variations and drug

- resistance. *F1000Research*, *5*, 2350.
<https://doi.org/10.12688/f1000research.9218.1>
- Lagorce, D., Bouslama, L., Becot, J., Miteva, M. A., & Villoutreix, B. O. (2017). FAF-Drugs4: free ADME-tox filtering computations for chemical biology and early stages drug discovery. *Bioinformatics*, *33*(22), 3658–3660.
<https://doi.org/10.1093/bioinformatics/btx491>
- Lakshmanan, I., & Batra, S. (2013). Protocol for Apoptosis Assay by Flow Cytometry Using Annexin V Staining Method. *BIO-PROTOCOL*, *3*(6).
<https://doi.org/10.21769/BioProtoc.374>
- Lander, N., & Chiurillo, M. A. (2019). State-of-the-art <sc>CRISPR</sc> /Cas9 Technology for Genome Editing in Trypanosomatids. *Journal of Eukaryotic Microbiology*, *66*(6), 981–991. <https://doi.org/10.1111/jeu.12747>
- Laskowski, R. A., & Swindells, M. B. (2011). LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery. *Journal of Chemical Information and Modeling*, *51*(10), 2778–2786. <https://doi.org/10.1021/ci200227u>
- Le, N.-A., & Walter, M. F. (2007). Intrinsic enzymes of high-density lipoprotein. *Journal of Clinical Lipidology*, *1*(1), 20–30. <https://doi.org/10.1016/j.jacl.2007.01.005>
- Lee, V. C.-J., Yao, J., & Zhang, W. (2021). The Health Impact Fund: making the case for engagement with pharmaceutical laboratories in Brazil, Russia, India, and China. *Globalization and Health*, *17*(1), 101. <https://doi.org/10.1186/s12992-021-00744-x>
- Légaré, D., & Ouellette, M. (2014). Drug Resistance in Leishmania. In *Handbook of Antimicrobial Resistance* (pp. 1–24). Springer New York.
https://doi.org/10.1007/978-1-4939-0667-3_17-1
- Lenz, M., Krauth-Siegel, R. L., & Schmidt, T. J. (2019). Natural Sesquiterpene Lactones of the 4,15-iso-Atriplicolide Type are Inhibitors of Trypanothione Reductase. *Molecules*, *24*(20), 3737. <https://doi.org/10.3390/molecules24203737>
- Leroux, A. E., & Krauth-Siegel, R. L. (2016). Thiol redox biology of trypanosomatids and potential targets for chemotherapy. *Molecular and Biochemical Parasitology*, *206*(1–2), 67–74. <https://doi.org/10.1016/j.molbiopara.2015.11.003>
- Li, B., Ming, H., Qin, S., Nice, E. C., Dong, J., Du, Z., & Huang, C. (2025). Redox regulation: mechanisms, biology and therapeutic targets in diseases. *Signal Transduction and Targeted Therapy*, *10*(1), 72. <https://doi.org/10.1038/s41392-024-02095-6>
- Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020). Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. *Signal Transduction and Targeted Therapy*, *5*(1), 1. <https://doi.org/10.1038/s41392-019-0089-y>

- Liévin-Le Moal, V., & Loiseau, P. M. (2016). *Leishmania* hijacking of the macrophage intracellular compartments. *The FEBS Journal*, 283(4), 598–607. <https://doi.org/10.1111/febs.13601>
- Liu, J., Wang, Y., Chen, C., Yu, C., Chen, L., Lin, J., Liang, Y., Lin, S., & Ho, Y. (2003). Molecular mechanisms of G₀/G₁ cell-cycle arrest and apoptosis induced by terfenadine in human cancer cells. *Molecular Carcinogenesis*, 37(1), 39–50. <https://doi.org/10.1002/mc.10118>
- Loiseau, P. M., Cojean, S., & Schrével, J. (2011). Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. *Parasite*, 18(2), 115–119. <https://doi.org/10.1051/parasite/2011182115>
- Lu, S. C. (2009). Regulation of glutathione synthesis. *Molecular Aspects of Medicine*, 30(1–2), 42–59. <https://doi.org/10.1016/j.mam.2008.05.005>
- Lye, L.-F., Dobson, D. E., Beverley, S. M., & Tung, M.-C. (2025). RNA interference in protozoan parasites and its application. *Journal of Microbiology, Immunology and Infection*. <https://doi.org/10.1016/j.jmii.2025.01.005>
- Lye, L.-F., Owens, K., Shi, H., Murta, S. M. F., Vieira, A. C., Turco, S. J., Tschudi, C., Ullu, E., & Beverley, S. M. (2010). Retention and Loss of RNA Interference Pathways in Trypanosomatid Protozoans. *PLoS Pathogens*, 6(10), e1001161. <https://doi.org/10.1371/journal.ppat.1001161>
- Lypaczewski, P., Hoshizaki, J., Zhang, W.-W., McCall, L.-I., Torcivia-Rodriguez, J., Simonyan, V., Kaur, A., Dewar, K., & Matlashewski, G. (2018). A complete *Leishmania donovani* reference genome identifies novel genetic variations associated with virulence. *Scientific Reports*, 8(1), 16549. <https://doi.org/10.1038/s41598-018-34812-x>
- Magnani, F., & Mattevi, A. (2019). Structure and mechanisms of ROS generation by NADPH oxidases. *Current Opinion in Structural Biology*, 59, 91–97. <https://doi.org/10.1016/j.sbi.2019.03.001>
- Mailloux, R. J. (2020). An Update on Mitochondrial Reactive Oxygen Species Production. *Antioxidants*, 9(6), 472. <https://doi.org/10.3390/antiox9060472>
- MANDAL, G., WYLLIE, S., SINGH, N., SUNDAR, S., FAIRLAMB, A. H., & CHATTERJEE, M. (2007a). Increased levels of thiols protect antimony unresponsive *Leishmania donovani* field isolates against reactive oxygen species generated by trivalent antimony. *Parasitology*, 134(12), 1679–1687. <https://doi.org/10.1017/S0031182007003150>
- MANDAL, G., WYLLIE, S., SINGH, N., SUNDAR, S., FAIRLAMB, A. H., & CHATTERJEE, M. (2007b). Increased levels of thiols protect antimony unresponsive *Leishmania donovani* field isolates against reactive oxygen species generated by trivalent antimony. *Parasitology*, 134(12), 1679–1687. <https://doi.org/10.1017/S0031182007003150>

- Manoharan, R. R., Prasad, A., Pospíšil, P., & Kzhyshkowska, J. (2024a). ROS signaling in innate immunity via oxidative protein modifications. *Frontiers in Immunology*, *15*. <https://doi.org/10.3389/fimmu.2024.1359600>
- Manoharan, R. R., Prasad, A., Pospíšil, P., & Kzhyshkowska, J. (2024b). ROS signaling in innate immunity via oxidative protein modifications. *Frontiers in Immunology*, *15*. <https://doi.org/10.3389/fimmu.2024.1359600>
- Mansuri, R., Kumar, A., Rana, S., Panthi, B., Ansari, M. Y., Das, S., Dikhit, M. R., Sahoo, G. C., & Das, P. (2017). *In Vitro* Evaluation of Antileishmanial Activity of Computationally Screened Compounds against Ascorbate Peroxidase To Combat Amphotericin B Drug Resistance. *Antimicrobial Agents and Chemotherapy*, *61*(7). <https://doi.org/10.1128/AAC.02429-16>
- Marciano, D., Santana, M., & Nowicki, C. (2012). Functional characterization of enzymes involved in cysteine biosynthesis and H₂S production in *Trypanosoma cruzi*. *Molecular and Biochemical Parasitology*, *185*(2), 114–120. <https://doi.org/10.1016/j.molbiopara.2012.07.009>
- Martinvalet, D., & Walch, M. (2022). Editorial: The Role of Reactive Oxygen Species in Protective Immunity. *Frontiers in Immunology*, *12*. <https://doi.org/10.3389/fimmu.2021.832946>
- Martoňák, R., Laio, A., & Parrinello, M. (2003). Predicting Crystal Structures: The Parrinello-Rahman Method Revisited. *Physical Review Letters*, *90*(7), 075503. <https://doi.org/10.1103/PhysRevLett.90.075503>
- Maruta, H., & He, H. (2020). PAK1-blockers: Potential Therapeutics against COVID-19. *Medicine in Drug Discovery*, *6*, 100039. <https://doi.org/10.1016/j.medidd.2020.100039>
- Matadamas-Martínez, F., Hernández-Campos, A., Téllez-Valencia, A., Vázquez-Raygoza, A., Comparán-Alarcón, S., Yépez-Mulia, L., & Castillo, R. (2019). Leishmania mexicana Trypanothione Reductase Inhibitors: Computational and Biological Studies. *Molecules*, *24*(18), 3216. <https://doi.org/10.3390/molecules24183216>
- Matheoud, D., Moradin, N., Bellemare-Pelletier, A., Shio, M. T., Hong, W. J., Olivier, M., Gagnon, É., Desjardins, M., & Descoteaux, A. (2013a). Leishmania Evades Host Immunity by Inhibiting Antigen Cross-Presentation through Direct Cleavage of the SNARE VAMP8. *Cell Host & Microbe*, *14*(1), 15–25. <https://doi.org/10.1016/j.chom.2013.06.003>
- Matheoud, D., Moradin, N., Bellemare-Pelletier, A., Shio, M. T., Hong, W. J., Olivier, M., Gagnon, É., Desjardins, M., & Descoteaux, A. (2013b). Leishmania Evades Host Immunity by Inhibiting Antigen Cross-Presentation through Direct Cleavage of the SNARE VAMP8. *Cell Host & Microbe*, *14*(1), 15–25. <https://doi.org/10.1016/j.chom.2013.06.003>
- Mesías, A. C., Sasoni, N., Arias, D. G., Pérez Brandán, C., Orban, O. C. F., Kunick, C., Robello, C., Comini, M. A., Garg, N. J., & Zago, M. P. (2019). Trypanothione

- synthetase confers growth, survival advantage and resistance to anti-protozoal drugs in *Trypanosoma cruzi*. *Free Radical Biology and Medicine*, 130, 23–34. <https://doi.org/10.1016/j.freeradbiomed.2018.10.436>
- Minadakis, G., Tomazou, M., Dietis, N., & Spyrou, G. M. (2023). Vir2Drug: a drug repurposing framework based on protein similarities between pathogens. *Briefings in Bioinformatics*, 24(1). <https://doi.org/10.1093/bib/bbac536>
- Moradin, N., & Descoteaux, A. (2012). Leishmania promastigotes: building a safe niche within macrophages. *Frontiers in Cellular and Infection Microbiology*, 2. <https://doi.org/10.3389/fcimb.2012.00121>
- Morris, G., Gevezova, M., Sarafian, V., & Maes, M. (2022). Redox regulation of the immune response. *Cellular & Molecular Immunology*, 19(10), 1079–1101. <https://doi.org/10.1038/s41423-022-00902-0>
- Moussa, Z., M.A. Judeh, Z., & A. Ahmed, S. (2020). Nonenzymatic Exogenous and Endogenous Antioxidants. In *Free Radical Medicine and Biology*. IntechOpen. <https://doi.org/10.5772/intechopen.87778>
- Mueller-Langer, F. (2013). Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research? *Health Economics, Policy and Law*, 8(2), 185–208. <https://doi.org/10.1017/S1744133112000321>
- Mukherjee, A. K., Gupta, G., Bhattacharjee, S., Guha, S. K., Majumder, S., Adhikari, A., Bhattacharya, P., Majumdar, S. B., & Majumdar, S. (2010). Amphotericin B regulates the host immune response in visceral leishmaniasis: Reciprocal regulation of protein kinase C isoforms. *Journal of Infection*, 61(2), 173–184. <https://doi.org/10.1016/j.jinf.2010.05.003>
- Mukherjee, A., Roy, G., Guimond, C., & Ouellette, M. (2009a). The γ -glutamylcysteine synthetase gene of *Leishmania* is essential and involved in response to oxidants. *Molecular Microbiology*, 74(4), 914–927. <https://doi.org/10.1111/j.1365-2958.2009.06907.x>
- Mukherjee, A., Roy, G., Guimond, C., & Ouellette, M. (2009b). The γ -glutamylcysteine synthetase gene of *Leishmania* is essential and involved in response to oxidants. *Molecular Microbiology*, 74(4), 914–927. <https://doi.org/10.1111/j.1365-2958.2009.06907.x>
- Muntjewerff, E. M., Meesters, L. D., & van den Bogaart, G. (2020). Antigen Cross-Presentation by Macrophages. *Frontiers in Immunology*, 11. <https://doi.org/10.3389/fimmu.2020.01276>
- Mutch, E., Nave, R., McCracken, N., Zech, K., & Williams, F. M. (2007). The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. *Biochemical Pharmacology*, 73(10), 1657–1664. <https://doi.org/10.1016/j.bcp.2007.01.031>

- Nafari, A., Cheraghpour, K., Sepahvand, M., Shahrokhi, G., Gabal, E., & Mahmoudvand, H. (2020). Nanoparticles: New agents toward treatment of leishmaniasis. *Parasite Epidemiology and Control*, *10*, e00156. <https://doi.org/10.1016/j.parepi.2020.e00156>
- Nagle, A. S., Khare, S., Kumar, A. B., Supek, F., Buchynskyy, A., Mathison, C. J. N., Chennamaneni, N. K., Pendem, N., Buckner, F. S., Gelb, M. H., & Molteni, V. (2014). Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. *Chemical Reviews*, *114*(22), 11305–11347. <https://doi.org/10.1021/cr500365f>
- Nath, M., Bhowmik, D., Saha, S., Nandi, R., & Kumar, D. (2024). Identification of potential inhibitor against *Leishmania donovani* mitochondrial DNA primase through in-silico and in vitro drug repurposing approaches. *Scientific Reports*, *14*(1), 3246. <https://doi.org/10.1038/s41598-024-53316-5>
- Negreira, G. H., de Groote, R., Van Giel, D., Monsieurs, P., Maes, I., de Muylder, G., Van den Broeck, F., Dujardin, J., & Domagalska, M. A. (2023). The adaptive roles of aneuploidy and polyclonality in *Leishmania* in response to environmental stress. *EMBO Reports*, *24*(9). <https://doi.org/10.15252/embr.202357413>
- Negreira, G. H., Monsieurs, P., Imamura, H., Maes, I., Kuk, N., Yagoubat, A., Van den Broeck, F., Sterkers, Y., Dujardin, J.-C., & Domagalska, M. A. (2022). High throughput single-cell genome sequencing gives insights into the generation and evolution of mosaic aneuploidy in *Leishmania donovani*. *Nucleic Acids Research*, *50*(1), 293–305. <https://doi.org/10.1093/nar/gkab1203>
- Neto, R. L. M., Sousa, L. M. A., Dias, C. S., Filho, J. M. B., Oliveira, M. R., & Figueiredo, R. C. B. Q. (2011). Morphological and physiological changes in *Leishmania* promastigotes induced by yangambin, a lignan obtained from *Ocotea duckei*. *Experimental Parasitology*, *127*(1), 215–221. <https://doi.org/10.1016/j.exppara.2010.07.020>
- No, J. H. (2016). Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries. *Acta Tropica*, *155*, 113–123. <https://doi.org/10.1016/j.actatropica.2015.12.016>
- Nozaki, T., Ali, V., & Tokoro, M. (2005). *Sulfur-Containing Amino Acid Metabolism in Parasitic Protozoa* (pp. 1–99). [https://doi.org/10.1016/S0065-308X\(05\)60001-2](https://doi.org/10.1016/S0065-308X(05)60001-2)
- Okwor, I., & Uzonna, J. (2016a). Social and Economic Burden of Human Leishmaniasis. *The American Society of Tropical Medicine and Hygiene*, *94*(3), 489–493. <https://doi.org/10.4269/ajtmh.15-0408>
- Okwor, I., & Uzonna, J. (2016b). Social and Economic Burden of Human Leishmaniasis. *The American Society of Tropical Medicine and Hygiene*, *94*(3), 489–493. <https://doi.org/10.4269/ajtmh.15-0408>
- Olin-Sandoval, V., González-Chávez, Z., Berzunza-Cruz, M., Martínez, I., Jasso-Chávez, R., Becker, I., Espinoza, B., Moreno-Sánchez, R., & Saavedra, E. (2012). Drug target validation of the trypanothione pathway enzymes through metabolic

- modelling. *The FEBS Journal*, 279(10), 1811–1833.
<https://doi.org/10.1111/j.1742-4658.2012.08557.x>
- Onrust, S. V., & Lamb, H. M. (1999a). Valrubicin. *Drugs & Aging*, 15(1), 69–75.
<https://doi.org/10.2165/00002512-199915010-00006>
- Onrust, S. V., & Lamb, H. M. (1999b). Valrubicin. *Drugs & Aging*, 15(1), 69–75.
<https://doi.org/10.2165/00002512-199915010-00006>
- Ortalli, M., Ilari, A., Colotti, G., De Ionna, I., Battista, T., Bisi, A., Gobbi, S., Rampa, A., Di Martino, R. M. C., Gentilomi, G. A., Varani, S., & Belluti, F. (2018). Identification of chalcone-based antileishmanial agents targeting trypanothione reductase. *European Journal of Medicinal Chemistry*, 152, 527–541.
<https://doi.org/10.1016/j.ejmech.2018.04.057>
- Oualha, R., Abdelkrim, Y. Z., Guizani, I., & Harigua-Souiai, E. (2024). Approved drugs successfully repurposed against Leishmania based on machine learning predictions. *Frontiers in Cellular and Infection Microbiology*, 14.
<https://doi.org/10.3389/fcimb.2024.1403589>
- Oza, S. L., Wyllie, S., & Fairlamb, A. H. (2006). Mapping the functional synthetase domain of trypanothione synthetase from *Leishmania major*. *Molecular and Biochemical Parasitology*, 149(1), 117–120.
<https://doi.org/10.1016/j.molbiopara.2006.05.001>
- Pace, D. (2014). Leishmaniasis. *Journal of Infection*, 69, S10–S18.
<https://doi.org/10.1016/j.jinf.2014.07.016>
- Pal, S., Dolai, S., Yadav, R. K., & Adak, S. (2010). Ascorbate Peroxidase from *Leishmania major* Controls the Virulence of Infective Stage of Promastigotes by Regulating Oxidative Stress. *PLoS ONE*, 5(6), e11271.
<https://doi.org/10.1371/journal.pone.0011271>
- Palić, S., Beijnen, J. H., & Dorlo, T. P. C. (2022). An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis. *International Journal of Antimicrobial Agents*, 59(1), 106459.
<https://doi.org/10.1016/j.ijantimicag.2021.106459>
- Paliwal, A., Gahtori, R., Kumari, A., & Pandey, P. (2021). Drug resistance and repurposing of existing drugs in Leishmaniasis. In *Pathogenesis, Treatment and Prevention of Leishmaniasis* (pp. 103–124). Elsevier.
<https://doi.org/10.1016/B978-0-12-822800-5.00013-5>
- Palomino-Cano, C., Moreno, E., Irache, J. M., & Espuelas, S. (2024a). Targeting and activation of macrophages in leishmaniasis. A focus on iron oxide nanoparticles. *Frontiers in Immunology*, 15. <https://doi.org/10.3389/fimmu.2024.1437430>
- Palomino-Cano, C., Moreno, E., Irache, J. M., & Espuelas, S. (2024b). Targeting and activation of macrophages in leishmaniasis. A focus on iron oxide nanoparticles. *Frontiers in Immunology*, 15. <https://doi.org/10.3389/fimmu.2024.1437430>

- Palomino-Cano, C., Moreno, E., Irache, J. M., & Espuelas, S. (2024c). Targeting and activation of macrophages in leishmaniasis. A focus on iron oxide nanoparticles. *Frontiers in Immunology*, *15*. <https://doi.org/10.3389/fimmu.2024.1437430>
- Pande, M., Kundu, D., & Srivastava, R. (2021). Drugs repurposing against SARS-CoV2 and the new variant B.1.1.7 (alpha strain) targeting the spike protein: molecular docking and simulation studies. *Heliyon*, *7*(8), e07803. <https://doi.org/10.1016/j.heliyon.2021.e07803>
- Paris, C., Loiseau, P. M., Bories, C., & Bréard, J. (2004). Miltefosine Induces Apoptosis-Like Death in *Leishmania donovani* Promastigotes. *Antimicrobial Agents and Chemotherapy*, *48*(3), 852–859. <https://doi.org/10.1128/AAC.48.3.852-859.2004>
- Patterson, S., Alphey, M. S., Jones, D. C., Shanks, E. J., Street, I. P., Frearson, J. A., Wyatt, P. G., Gilbert, I. H., & Fairlamb, A. H. (2011). Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography. *Journal of Medicinal Chemistry*, *54*(19), 6514–6530. <https://doi.org/10.1021/jm200312v>
- Pei, J., & Grishin, N. V. (2014). *PROMALS3D: Multiple Protein Sequence Alignment Enhanced with Evolutionary and Three-Dimensional Structural Information* (pp. 263–271). https://doi.org/10.1007/978-1-62703-646-7_17
- Pei, J., Pan, X., Wei, G., & Hua, Y. (2023). Research progress of glutathione peroxidase family (GPX) in redoxidation. *Frontiers in Pharmacology*, *14*. <https://doi.org/10.3389/fphar.2023.1147414>
- Piccica, M., Lagi, F., Bartoloni, A., & Zammarchi, L. (2021). Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review. *Journal of Travel Medicine*, *28*(6). <https://doi.org/10.1093/jtm/taab065>
- Pietkiewicz, S., Schmidt, J. H., & Lavrik, I. N. (2015). Quantification of apoptosis and necroptosis at the single cell level by a combination of Imaging Flow Cytometry with classical Annexin V/propidium iodide staining. *Journal of Immunological Methods*, *423*, 99–103. <https://doi.org/10.1016/j.jim.2015.04.025>
- Pinheiro, A. C., & de Souza, M. V. N. (2022). Current leishmaniasis drug discovery. *RSC Medicinal Chemistry*, *13*(9), 1029–1043. <https://doi.org/10.1039/D1MD00362C>
- Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D., & Bitto, A. (2017). Oxidative Stress: Harms and Benefits for Human Health. *Oxidative Medicine and Cellular Longevity*, *2017*(1). <https://doi.org/10.1155/2017/8416763>
- Polonio. (1998). Leishmaniasis: Drug resistance and natural products (Review). *International Journal of Molecular Medicine*. https://doi.org/10.3892/ijmm_00000020

- Pratt, C., Nguyen, S., & Phillips, M. A. (2014). Genetic Validation of Trypanosoma brucei Glutathione Synthetase as an Essential Enzyme. *Eukaryotic Cell*, 13(5), 614–624. <https://doi.org/10.1128/EC.00015-14>
- Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: progress, challenges and recommendations. *Nature Reviews Drug Discovery*, 18(1), 41–58. <https://doi.org/10.1038/nrd.2018.168>
- Raboisson, P., de Kock, H., Rosenquist, Å., Nilsson, M., Salvador-Oden, L., Lin, T.-I., Roue, N., Ivanov, V., Wähling, H., Wickström, K., Hamelink, E., Edlund, M., Vrang, L., Vendeville, S., Van de Vreken, W., McGowan, D., Tahri, A., Hu, L., Boutton, C., ... Simmen, K. (2008). Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. *Bioorganic & Medicinal Chemistry Letters*, 18(17), 4853–4858. <https://doi.org/10.1016/j.bmcl.2008.07.088>
- Raj, S., Sasidharan, S., Balaji, S. N., & Saudagar, P. (2020). An overview of biochemically characterized drug targets in metabolic pathways of Leishmania parasite. *Parasitology Research*, 119(7), 2025–2037. <https://doi.org/10.1007/s00436-020-06736-x>
- Ramos, H., Valdivieso, E., Gamargo, M., Dagger, F., & Cohen, B. E. (1996). Amphotericin B Kills Unicellular Leishmanias by Forming Aqueous Pores Permeable to Small Cations and Anions. *Journal of Membrane Biology*, 152(1), 65–75. <https://doi.org/10.1007/s002329900086>
- Ramu, D., Garg, S., Ayana, R., Keerthana, A. K., Sharma, V., Saini, C. P., Sen, S., Pati, S., & Singh, S. (2017). Novel β-carboline-quinazolinone hybrids disrupt Leishmania donovani redox homeostasis and show promising antileishmanial activity. *Biochemical Pharmacology*, 129, 26–42. <https://doi.org/10.1016/j.bcp.2016.12.012>
- Ranjan, P., & Dubey, V. K. (2023). Novel chemical scaffold as potential drug against *Leishmania donovani*: Integrated computational and experimental approaches. *Journal of Cellular Biochemistry*, 124(9), 1404–1422. <https://doi.org/10.1002/jcb.30455>
- Reverte, M., Snäkä, T., & Fasel, N. (2022). The Dangerous Liaisons in the Oxidative Stress Response to Leishmania Infection. *Pathogens*, 11(4), 409. <https://doi.org/10.3390/pathogens11040409>
- Rhee, S. G. (2006). H₂O₂, a Necessary Evil for Cell Signaling. *Science*, 312(5782), 1882–1883. <https://doi.org/10.1126/science.1130481>
- Ricci, J.-E., Muñoz-Pinedo, C., Fitzgerald, P., Bailly-Maitre, B., Perkins, G. A., Yadava, N., Scheffler, I. E., Ellisman, M. H., & Green, D. R. (2004). Disruption of Mitochondrial Function during Apoptosis Is Mediated by Caspase Cleavage of the

p75 Subunit of Complex I of the Electron Transport Chain. *Cell*, 117(6), 773–786. <https://doi.org/10.1016/j.cell.2004.05.008>

- Roberts, A. J., Ong, H. B., Clare, S., Brandt, C., Harcourt, K., Franssen, S. U., Cotton, J. A., Müller-Sienerth, N., & Wright, G. J. (2022). Systematic identification of genes encoding cell surface and secreted proteins that are essential for in vitro growth and infection in *Leishmania donovani*. *PLOS Pathogens*, 18(2), e1010364. <https://doi.org/10.1371/journal.ppat.1010364>
- Robinson, K. A., & Beverley, S. M. (2003). Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite *Leishmania*. *Molecular and Biochemical Parasitology*, 128(2), 217–228. [https://doi.org/10.1016/S0166-6851\(03\)00079-3](https://doi.org/10.1016/S0166-6851(03)00079-3)
- Rodrigues, J. C. F., Godinho, J. L. P., & de Souza, W. (2014). *Biology of Human Pathogenic Trypanosomatids: Epidemiology, Lifecycle and Ultrastructure* (pp. 1–42). https://doi.org/10.1007/978-94-007-7305-9_1
- Rogers, M. B., Hilley, J. D., Dickens, N. J., Wilkes, J., Bates, P. A., Depledge, D. P., Harris, D., Her, Y., Herzyk, P., Imamura, H., Otto, T. D., Sanders, M., Seeger, K., Dujardin, J.-C., Berriman, M., Smith, D. F., Hertz-Fowler, C., & Mottram, J. C. (2011a). Chromosome and gene copy number variation allow major structural change between species and strains of *Leishmania*. *Genome Research*, 21(12), 2129–2142. <https://doi.org/10.1101/gr.122945.111>
- Rogers, M. B., Hilley, J. D., Dickens, N. J., Wilkes, J., Bates, P. A., Depledge, D. P., Harris, D., Her, Y., Herzyk, P., Imamura, H., Otto, T. D., Sanders, M., Seeger, K., Dujardin, J.-C., Berriman, M., Smith, D. F., Hertz-Fowler, C., & Mottram, J. C. (2011b). Chromosome and gene copy number variation allow major structural change between species and strains of *Leishmania*. *Genome Research*, 21(12), 2129–2142. <https://doi.org/10.1101/gr.122945.111>
- Romero, I., Téllez, J., Yamanaka, L., Steindel, M., Romanha, A., & Grisard, E. (2014). Transsulfuration is an active pathway for cysteine biosynthesis in *Trypanosoma rangeli*. *Parasites & Vectors*, 7(1), 197. <https://doi.org/10.1186/1756-3305-7-197>
- Sadr, S., Sharifi, I., Morovati, S., Sepahvand, H., Nazemian, S., Bamorovat, M., Rezaeian, Z., & Akhtardanesh, B. (2025). An inclusive assessment of apoptosis mechanisms in *Leishmania* species: A narrative literature review. *Current Research in Parasitology & Vector-Borne Diseases*, 7, 100260. <https://doi.org/10.1016/j.crpvbd.2025.100260>
- Saha, G., Chiranjivi, A. K., Khamar, B. M., Prerna, K., Kumar, M., & Dubey, V. K. (2020). BLIMP-1 Mediated Downregulation of TAK1 and p53 Molecules Is Crucial in the Pathogenesis of Kala-Azar. *Frontiers in Cellular and Infection Microbiology*, 10. <https://doi.org/10.3389/fcimb.2020.594431>
- Santacroce, G., Gentile, A., Soriano, S., Novelli, A., Lenti, M. V., & Di Sabatino, A. (2023). Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease. *Frontiers in Medicine*, 10. <https://doi.org/10.3389/fmed.2023.1124275>

- Santi, A. M. M., & Murta, S. M. F. (2022). Impact of Genetic Diversity and Genome Plasticity of *Leishmania* spp. in Treatment and the Search for Novel Chemotherapeutic Targets. *Frontiers in Cellular and Infection Microbiology*, 12. <https://doi.org/10.3389/fcimb.2022.826287>
- Santos, S. S., de Araújo, R. V., Giarolla, J., Seoud, O. El, & Ferreira, E. I. (2020). Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review. *International Journal of Antimicrobial Agents*, 55(4), 105906. <https://doi.org/10.1016/j.ijantimicag.2020.105906>
- Saravanamuthu, A., Vickers, T. J., Bond, C. S., Peterson, M. R., Hunter, W. N., & Fairlamb, A. H. (2004). Two Interacting Binding Sites for Quinacrine Derivatives in the Active Site of Trypanothione Reductase. *Journal of Biological Chemistry*, 279(28), 29493–29500. <https://doi.org/10.1074/jbc.M403187200>
- Sarma, M., Borkotoky, S., & Dubey, V. K. (2024). Structure-based drug designing against *Leishmania donovani* using docking and molecular dynamics simulation studies: exploring glutathione synthetase as a drug target. *Journal of Biomolecular Structure and Dynamics*, 42(14), 7628–7636. <https://doi.org/10.1080/07391102.2023.2240429>
- Saudagar, P., & Dubey, V. K. (2011a). Cloning, expression, characterization and inhibition studies on trypanothione synthetase, a drug target enzyme, from *Leishmania donovani*. *Biological Chemistry*, 392(12), 1113–1122. <https://doi.org/10.1515/BC.2011.222>
- Saudagar, P., & Dubey, V. K. (2011b). Cloning, expression, characterization and inhibition studies on trypanothione synthetase, a drug target enzyme, from *Leishmania donovani*. *Biological Chemistry*, 392(12), 1113–1122. <https://doi.org/10.1515/BC.2011.222>
- Saudagar, P., & Dubey, V. K. (2014a). Molecular Mechanisms of In vitro Betulin-Induced Apoptosis of *Leishmania donovani*. *The American Society of Tropical Medicine and Hygiene*, 90(2), 354–360. <https://doi.org/10.4269/ajtmh.13-0320>
- Saudagar, P., & Dubey, V. K. (2014b). Molecular Mechanisms of In vitro Betulin-Induced Apoptosis of *Leishmania donovani*. *The American Society of Tropical Medicine and Hygiene*, 90(2), 354–360. <https://doi.org/10.4269/ajtmh.13-0320>
- Saudagar, P., Saha, P., Saikia, A. K., & Dubey, V. K. (2013). Molecular mechanism underlying antileishmanial effect of oxabicyclo[3.3.1]nonanones: Inhibition of key redox enzymes of the pathogen. *European Journal of Pharmaceutics and Biopharmaceutics*, 85(3), 569–577. <https://doi.org/10.1016/j.ejpb.2013.08.014>
- Saxena, A., Lakshmi, J., Bhattacharjya, R., Singh, P. K., Mishra, B., & Tiwari, A. (2023). The role of antioxidant enzymes in diatoms and their therapeutic role. In *Marine Antioxidants* (pp. 89–118). Elsevier. <https://doi.org/10.1016/B978-0-323-95086-2.00019-9>

- Schieber, M., & Chandel, N. S. (2014). ROS Function in Redox Signaling and Oxidative Stress. *Current Biology*, 24(10), R453–R462. <https://doi.org/10.1016/j.cub.2014.03.034>
- Schlecker, T., Schmidt, A., Dirdjaja, N., Voncken, F., Clayton, C., & Krauth-Siegel, R. L. (2005). Substrate Specificity, Localization, and Essential Role of the Glutathione Peroxidase-type Tryparedoxin Peroxidases in *Trypanosoma brucei*. *Journal of Biological Chemistry*, 280(15), 14385–14394. <https://doi.org/10.1074/jbc.M413338200>
- Sen, N., Das, B. B., Ganguly, A., Mukherjee, T., Tripathi, G., Bandyopadhyay, S., Rakshit, S., Sen, T., & Majumder, H. K. (2004). Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate *Leishmania donovani*. *Cell Death & Differentiation*, 11(8), 924–936. <https://doi.org/10.1038/sj.cdd.4401435>
- Shames, S. L., Fairlamb, A. H., Cerami, A., & Walsh, C. T. (1986). Purification and characterization of trypanothione reductase from *Crithidia fasciculata*, a new member of the family of disulfide-containing flavoprotein reductases. *Biochemistry*, 25(12), 3519–3526. <https://doi.org/10.1021/bi00360a007>
- Sharma, R., Avendaño Rangel, F., Reis-Cunha, J. L., Marques, L. P., Figueira, C. P., Borba, P. B., Viana, S. M., Beneke, T., Bartholomeu, D. C., & de Oliveira, C. I. (2022). Targeted Deletion of Centrin in *Leishmania braziliensis* Using CRISPR-Cas9-Based Editing. *Frontiers in Cellular and Infection Microbiology*, 11. <https://doi.org/10.3389/fcimb.2021.790418>
- Sherwood, J. A., Gachihi, G. S., Muigai, R. K., Skillman, D. R., Mugo, M., Rashid, J. R., Wasunna, K. M. A., Were, J. B. O., Kasili, S. K., Mbugua, J. M., Kirigi, G., Schaefer, K. U., Oster, C. N., Fleckenstein, L. L., Berman, J. D., Brewer, T. G., Roberts, C. R., Johnson, A. J., & Schuster, B. G. (1994). Phase 2 Efficacy Trial of an Oral 8-Aminoquinoline (WR6026) for Treatment of Visceral Leishmaniasis. *Clinical Infectious Diseases*, 19(6), 1034–1039. <https://doi.org/10.1093/clinids/19.6.1034>
- Shio, M. T., Hassani, K., Isnard, A., Ralph, B., Contreras, I., Gomez, M. A., Abu-Dayyeh, I., & Olivier, M. (2012). Host Cell Signalling and *Leishmania* Mechanisms of Evasion. *Journal of Tropical Medicine*, 2012, 1–14. <https://doi.org/10.1155/2012/819512>
- Simon, J. (2012). Chemistry and Pharmacy. In *Philosophy of Chemistry* (pp. 519–530). Elsevier. <https://doi.org/10.1016/B978-0-444-51675-6.50033-5>
- Sindermann, H., & Engel, J. (2006). Development of miltefosine as an oral treatment for leishmaniasis. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 100, S17–S20. <https://doi.org/10.1016/j.trstmh.2006.02.010>
- Singh, K., Ali, V., Pratap Singh, K., Gupta, P., Suman, S. S., Ghosh, A. K., Bimal, S., Pandey, K., & Das, P. (2017). Deciphering the interplay between cysteine synthase and thiol cascade proteins in modulating Amphotericin B resistance and

- survival of *Leishmania donovani* under oxidative stress. *Redox Biology*, 12, 350–366. <https://doi.org/10.1016/j.redox.2017.03.004>
- Singh, K., Singh, K. P., Equbal, A., Suman, S. S., Zaidi, A., Garg, G., Pandey, K., Das, P., & Ali, V. (2016). Interaction between cysteine synthase and serine O-acetyltransferase proteins and their stage specific expression in *Leishmania donovani*. *Biochimie*, 131, 29–44. <https://doi.org/10.1016/j.biochi.2016.09.004>
- Singh, O. P., Singh, B., Chakravarty, J., & Sundar, S. (2016). Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. *Infectious Diseases of Poverty*, 5(1), 19. <https://doi.org/10.1186/s40249-016-0112-2>
- Sinha, R., C, M. M., Raghwan, Das, S., Das, S., Shadab, M., Chowdhury, R., Tripathy, S., & Ali, N. (2018). Genome Plasticity in Cultured *Leishmania donovani*: Comparison of Early and Late Passages. *Frontiers in Microbiology*, 9. <https://doi.org/10.3389/fmicb.2018.01279>
- Smithson, D. C., Lee, J., Shelat, A. A., Phillips, M. A., & Guy, R. K. (2010). Discovery of Potent and Selective Inhibitors of *Trypanosoma brucei* Ornithine Decarboxylase. *Journal of Biological Chemistry*, 285(22), 16771–16781. <https://doi.org/10.1074/jbc.M109.081588>
- Song, X., Zhang, Y., Wang, X., Zhang, W., Wang, Z., Zhang, F., Zhang, Y., Lu, J., Mei, J., Hu, Y., Chen, L., Li, H., Ye, Y., Liu, Y., & Gu, J. (2017). Casticin induces apoptosis and G0/G1 cell cycle arrest in gallbladder cancer cells. *Cancer Cell International*, 17(1), 9. <https://doi.org/10.1186/s12935-016-0377-3>
- Sousa, A. F., Gomes-Alves, A. G., Benítez, D., Comini, M. A., Flohé, L., Jaeger, T., Passos, J., Stuhlmann, F., Tomás, A. M., & Castro, H. (2014). Genetic and chemical analyses reveal that trypanothione synthetase but not glutathionylspermidine synthetase is essential for *Leishmania infantum*. *Free Radical Biology and Medicine*, 73, 229–238. <https://doi.org/10.1016/j.freeradbiomed.2014.05.007>
- Sterkers, Y., Crobu, L., Lachaud, L., Pagès, M., & Bastien, P. (2014). Parasexuality and mosaic aneuploidy in *Leishmania*: alternative genetics. *Trends in Parasitology*, 30(9), 429–435. <https://doi.org/10.1016/j.pt.2014.07.002>
- Sterkers, Y., Lachaud, L., Crobu, L., Bastien, P., & Pagès, M. (2011). FISH analysis reveals aneuploidy and continual generation of chromosomal mosaicism in *Leishmania major*. *Cellular Microbiology*, 13(2), 274–283. <https://doi.org/10.1111/j.1462-5822.2010.01534.x>
- Sterling, T., & Irwin, J. J. (2015). ZINC 15 – Ligand Discovery for Everyone. *Journal of Chemical Information and Modeling*, 55(11), 2324–2337. <https://doi.org/10.1021/acs.jcim.5b00559>
- Suman, S. K., Khatri, M., Dhawaria, M., Kurmi, A., Pandey, D., Ghosh, S., & Jain, S. I. (2018). Potential of *Trametes maxima* IIPLC-32 derived laccase for the detoxification of phenolic inhibitors in lignocellulosic biomass prehydrolysate.

International Biodeterioration & Biodegradation, 133, 1–8.
<https://doi.org/10.1016/j.ibiod.2018.05.009>

- Suman, S. S., Equbal, A., Zaidi, A., Ansari, Md. Y., Singh, K. P., Singh, K., Purkait, B., Sahoo, G. C., Bimal, S., Das, P., & Ali, V. (2016). Up-regulation of cytosolic trypanothione in Amp B resistant isolates of *Leishmania donovani* and its interaction with cytosolic trypanothione peroxidase. *Biochimie*, 121, 312–325. <https://doi.org/10.1016/j.biochi.2015.12.017>
- Sun, D., Jones, L. H., Mathews, F. S., & Davidson, V. L. (2001). Active-site residues are critical for the folding and stability of methylamine dehydrogenase. *Protein Engineering, Design and Selection*, 14(9), 675–681. <https://doi.org/10.1093/protein/14.9.675>
- Sundar, S., & Chakravarty, J. (2015). An update on pharmacotherapy for leishmaniasis. *Expert Opinion on Pharmacotherapy*, 16(2), 237–252. <https://doi.org/10.1517/14656566.2015.973850>
- Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002). Oral Miltefosine for Indian Visceral Leishmaniasis. *New England Journal of Medicine*, 347(22), 1739–1746. <https://doi.org/10.1056/NEJMoa021556>
- Sundar, S., & Olliaro, P. L. (2007). Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. *Therapeutics and Clinical Risk Management*, 3(5), 733–740.
- Sundar, S., Singh, A., Rai, M., Prajapati, V. K., Singh, A. K., Ostyn, B., Boelaert, M., Dujardin, J.-C., & Chakravarty, J. (2012). Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use. *Clinical Infectious Diseases*, 55(4), 543–550. <https://doi.org/10.1093/cid/cis474>
- Sundar, S., Singh, J., Singh, V. K., Agrawal, N., & Kumar, R. (2024). Current and emerging therapies for the treatment of leishmaniasis. *Expert Opinion on Orphan Drugs*, 12(1), 19–32. <https://doi.org/10.1080/21678707.2024.2335248>
- Tabrez, S., Rahman, F., Ali, R., Muhammad, F., Alshehri, B. M., Alaidarous, M. A., Banawas, S., Dukhyil, A. A. Bin, & Rub, A. (2021). Repurposing of FDA-approved drugs as inhibitors of sterol C-24 methyltransferase of *Leishmania donovani* to fight against leishmaniasis. *Drug Development Research*, 82(8), 1154–1161. <https://doi.org/10.1002/ddr.21820>
- Tamir, M., Birke Teketelew, B., Berta, D. M., Angelo, A. A., Terekegne, A. M., Cherie, N., Mekonnen, G. G., Abere, A., & Eshetu, T. (2025). Review of host-directed immunotherapy and candidate agents against leishmaniasis. *Frontiers in Tropical Diseases*, 6. <https://doi.org/10.3389/fitd.2025.1450908>
- Teixeira, D. E., Benchimol, M., Rodrigues, J. C. F., Crepaldi, P. H., Pimenta, P. F. P., & de Souza, W. (2013). The Cell Biology of *Leishmania*: How to Teach Using Animations. *PLoS Pathogens*, 9(10), e1003594. <https://doi.org/10.1371/journal.ppat.1003594>

- Tetaud, E., Manai, F., Barrett, M. P., Nadeau, K., Walsh, C. T., & Fairlamb, A. H. (1998). Cloning and Characterization of the Two Enzymes Responsible for Trypanothione Biosynthesis in *Crithidia fasciculata*. *Journal of Biological Chemistry*, 273(31), 19383–19390. <https://doi.org/10.1074/jbc.273.31.19383>
- Thakur, C. P., Dedet, J. P., Narain, S., & Pratlong, F. (2001). Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 95(2), 187–189. [https://doi.org/10.1016/S0035-9203\(01\)90160-9](https://doi.org/10.1016/S0035-9203(01)90160-9)
- Thangaraj, K., Balasubramanian, B., Park, S., Natesan, K., Liu, W., & Manju, V. (2019). Orientin Induces G0/G1 Cell Cycle Arrest and Mitochondria Mediated Intrinsic Apoptosis in Human Colorectal Carcinoma HT29 Cells. *Biomolecules*, 9(9), 418. <https://doi.org/10.3390/biom9090418>
- Tiwari, N., Gedda, M. R., Tiwari, V. K., Singh, S. P., & Singh, R. K. (2017). Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis. *Mini-Reviews in Medicinal Chemistry*, 18(1). <https://doi.org/10.2174/1389557517666170425105129>
- Tiwari, N., Kumar, A., Singh, A. K., Bajpai, S., Agrahari, A. K., Kishore, D., Tiwari, V. K., & Singh, R. K. (2019). Leishmaniasis control: limitations of current drugs and prospects of natural products. In *Discovery and Development of Therapeutics from Natural Products Against Neglected Tropical Diseases* (pp. 293–350). Elsevier. <https://doi.org/10.1016/B978-0-12-815723-7.00008-0>
- Tomás, A. M., & Castro, H. (2013). Redox Metabolism in Mitochondria of Trypanosomatids. *Antioxidants & Redox Signaling*, 19(7), 696–707. <https://doi.org/10.1089/ars.2012.4948>
- Tomiotto-Pellissier, F., Bortoleti, B. T. da S., Assolini, J. P., Gonçalves, M. D., Carloto, A. C. M., Miranda-Sapla, M. M., Conchon-Costa, I., Bordignon, J., & Pavanelli, W. R. (2018). Macrophage Polarization in Leishmaniasis: Broadening Horizons. *Frontiers in Immunology*, 9. <https://doi.org/10.3389/fimmu.2018.02529>
- Torres-Santos, E. C. (2018). Leishmaniasis treatment update of possibilities for drug repurposing. *Frontiers in Bioscience*, 23(3), 4629. <https://doi.org/10.2741/4629>
- Torrie, L. S., Wyllie, S., Spinks, D., Oza, S. L., Thompson, S., Harrison, J. R., Gilbert, I. H., Wyatt, P. G., Fairlamb, A. H., & Frearson, J. A. (2009). Chemical Validation of Trypanothione Synthetase. *Journal of Biological Chemistry*, 284(52), 36137–36145. <https://doi.org/10.1074/jbc.M109.045336>
- Tovar, J., Cunningham, M. L., Smith, A. C., Croft, S. L., & Fairlamb, A. H. (1998). Down-regulation of *Leishmania donovani* trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: Effect on parasite intracellular survival. *Proceedings of the National Academy of Sciences*, 95(9), 5311–5316. <https://doi.org/10.1073/pnas.95.9.5311>
- Tovar, J., Wilkinson, S., Mottram, J. C., & Fairlamb, A. H. (1998). Evidence that trypanothione reductase is an essential enzyme in *Leishmania* by targeted

- replacement of the *tryA* gene locus. *Molecular Microbiology*, 29(2), 653–660. <https://doi.org/10.1046/j.1365-2958.1998.00968.x>
- Turcano, L., Battista, T., De Haro, E. T., Missineo, A., Alli, C., Paonessa, G., Colotti, G., Harper, S., Fiorillo, A., Ilari, A., & Bresciani, A. (2020). Spiro-containing derivatives show antiparasitic activity against *Trypanosoma brucei* through inhibition of the trypanothione reductase enzyme. *PLOS Neglected Tropical Diseases*, 14(5), e0008339. <https://doi.org/10.1371/journal.pntd.0008339>
- Turcano, L., Torrente, E., Missineo, A., Andreini, M., Gramiccia, M., Di Muccio, T., Genovese, I., Fiorillo, A., Harper, S., Bresciani, A., Colotti, G., & Ilari, A. (2018a). Identification and binding mode of a novel *Leishmania* Trypanothione reductase inhibitor from high throughput screening. *PLOS Neglected Tropical Diseases*, 12(11), e0006969. <https://doi.org/10.1371/journal.pntd.0006969>
- Turcano, L., Torrente, E., Missineo, A., Andreini, M., Gramiccia, M., Di Muccio, T., Genovese, I., Fiorillo, A., Harper, S., Bresciani, A., Colotti, G., & Ilari, A. (2018b). Identification and binding mode of a novel *Leishmania* Trypanothione reductase inhibitor from high throughput screening. *PLOS Neglected Tropical Diseases*, 12(11), e0006969. <https://doi.org/10.1371/journal.pntd.0006969>
- Turrens, J. F. (2004). Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa. *Molecular Aspects of Medicine*, 25(1–2), 211–220. <https://doi.org/10.1016/j.mam.2004.02.021>
- UniProt: a worldwide hub of protein knowledge. (2019). *Nucleic Acids Research*, 47(D1), D506–D515. <https://doi.org/10.1093/nar/gky1049>
- Ursini, F., Maiorino, M., & Forman, H. J. (2016). Redox homeostasis: The Golden Mean of healthy living. *Redox Biology*, 8, 205–215. <https://doi.org/10.1016/j.redox.2016.01.010>
- Ushio-Fukai, M., Ash, D., Nagarkoti, S., Belin de Chantemèle, E. J., Fulton, D. J. R., & Fukai, T. (2021). Interplay Between Reactive Oxygen/Reactive Nitrogen Species and Metabolism in Vascular Biology and Disease. *Antioxidants & Redox Signaling*, 34(16), 1319–1354. <https://doi.org/10.1089/ars.2020.8161>
- V. M., V., Dubey, V. K., & Ponnuraj, K. (2018). Identification of two natural compound inhibitors of *Leishmania donovani* Spermidine Synthase (SpdS) through molecular docking and dynamic studies. *Journal of Biomolecular Structure and Dynamics*, 36(10), 2678–2693. <https://doi.org/10.1080/07391102.2017.1366947>
- van Griensven, J., Dorlo, T. P., Diro, E., Costa, C., & Burza, S. (2024). The status of combination therapy for visceral leishmaniasis: an updated review. *The Lancet Infectious Diseases*, 24(1), e36–e46. [https://doi.org/10.1016/S1473-3099\(23\)00353-5](https://doi.org/10.1016/S1473-3099(23)00353-5)
- Varikuti, S., Jha, B. K., Volpedo, G., Ryan, N. M., Halsey, G., Hamza, O. M., McGwire, B. S., & Satoskar, A. R. (2018). Host-Directed Drug Therapies for Neglected Tropical Diseases Caused by Protozoan Parasites. *Frontiers in Microbiology*, 9. <https://doi.org/10.3389/fmicb.2018.02655>

- Venkatesan, S. K., Shukla, A. K., & Dubey, V. K. (2010). Molecular docking studies of selected tricyclic and quinone derivatives on trypanothione reductase of *Leishmania infantum*. *Journal of Computational Chemistry*, 31(13), 2463–2475. <https://doi.org/10.1002/jcc.21538>
- Villalpando-Rodriguez, G. E., & Gibson, S. B. (2021). Reactive Oxygen Species (ROS) Regulates Different Types of Cell Death by Acting as a Rheostat. *Oxidative Medicine and Cellular Longevity*, 2021(1). <https://doi.org/10.1155/2021/9912436>
- Volkov, O. A., Brockway, A. J., Wring, S. A., Peel, M., Chen, Z., Phillips, M. A., & De Brabander, J. K. (2018). Species-Selective Pyrimidineamine Inhibitors of *Trypanosoma brucei* S-Adenosylmethionine Decarboxylase. *Journal of Medicinal Chemistry*, 61(3), 1182–1203. <https://doi.org/10.1021/acs.jmedchem.7b01654>
- Walker, M. C., & van der Donk, W. A. (2016). The many roles of glutamate in metabolism. *Journal of Industrial Microbiology and Biotechnology*, 43(2–3), 419–430. <https://doi.org/10.1007/s10295-015-1665-y>
- Wang, P., Geng, J., Gao, J., Zhao, H., Li, J., Shi, Y., Yang, B., Xiao, C., Linghu, Y., Sun, X., Chen, X., Hong, L., Qin, F., Li, X., Yu, J.-S., You, H., Yuan, Z., Zhou, D., Johnson, R. L., & Chen, L. (2019). Macrophage achieves self-protection against oxidative stress-induced ageing through the Mst-Nrf2 axis. *Nature Communications*, 10(1), 755. <https://doi.org/10.1038/s41467-019-08680-6>
- Wasunna, M. K., Rashid, J. R., Mbui, J., Kirigi, G., Kinoti, D., Lodenyo, H., Felton, J. M., Sabin, A. J., Albert, M. J., & Horton, J. (2005). A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. *The American Journal of Tropical Medicine and Hygiene*, 73(5), 871–876.
- Weng, H.-B., Chen, H.-X., & Wang, M.-W. (2018). Innovation in neglected tropical disease drug discovery and development. *Infectious Diseases of Poverty*, 7(1), 67. <https://doi.org/10.1186/s40249-018-0444-1>
- Wijnant, G.-J., Dumetz, F., Dirx, L., Bulté, D., Cuypers, B., Van Bocxlaer, K., & Hendrickx, S. (2022). Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis. *Frontiers in Tropical Diseases*, 3. <https://doi.org/10.3389/fitd.2022.837460>
- Wilkinson, S. R., Meyer, D. J., Taylor, M. C., Bromley, E. V., Miles, M. A., & Kelly, J. M. (2002). The *Trypanosoma cruzi* Enzyme TcGPXI Is a Glycosomal Peroxidase and Can Be Linked to Trypanothione Reduction by Glutathione or Tryparedoxin. *Journal of Biological Chemistry*, 277(19), 17062–17071. <https://doi.org/10.1074/jbc.M111126200>
- World Health Organization. (2025, March 25). *Leishmaniasis*. <https://www.who.int/news-room/fact-sheets/detail/leishmaniasis>.
- Wyllie, S., Cunningham, M. L., & Fairlamb, A. H. (2004). Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen *Leishmania donovani*. *Journal of Biological Chemistry*, 279(38), 39925–39932. <https://doi.org/10.1074/jbc.M405635200>

- Wyllie, S., Mandal, G., Singh, N., Sundar, S., Fairlamb, A. H., & Chatterjee, M. (2010). Elevated levels of trypanothione peroxidase in antimony unresponsive *Leishmania donovani* field isolates. *Molecular and Biochemical Parasitology*, 173(2), 162–164. <https://doi.org/10.1016/j.molbiopara.2010.05.015>
- Yagoubat, A., Crobu, L., Berry, L., Kuk, N., Lefebvre, M., Sarrazin, A., Bastien, P., & Sterkers, Y. (2020). Universal highly efficient conditional knockout system in *Leishmania*, with a focus on untranscribed region preservation. *Cellular Microbiology*, 22(5). <https://doi.org/10.1111/cmi.13159>
- Yang, J., Roy, A., & Zhang, Y. (2013). Protein–ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. *Bioinformatics*, 29(20), 2588–2595. <https://doi.org/10.1093/bioinformatics/btt447>
- Young, J., & Kima, P. E. (2019). The *Leishmania* Parasitophorous Vacuole Membrane at the Parasite-Host Interface. *The Yale Journal of Biology and Medicine*, 92(3), 511–521.
- Yu, J.-L., Dai, Q.-Q., & Li, G.-B. (2022). Deep learning in target prediction and drug repositioning: Recent advances and challenges. *Drug Discovery Today*, 27(7), 1796–1814. <https://doi.org/10.1016/j.drudis.2021.10.010>
- Yuan, S., Chan, H. C. S., & Hu, Z. (2017). Using <sc>PyMOL</sc> as a platform for computational drug design. *WIREs Computational Molecular Science*, 7(2). <https://doi.org/10.1002/wcms.1298>
- Zangger, H., Mottram, J. C., & Fasel, N. (2002a). Cell death in *Leishmania* induced by stress and differentiation: programmed cell death or necrosis? *Cell Death & Differentiation*, 9(10), 1126–1139. <https://doi.org/10.1038/sj.cdd.4401071>
- Zangger, H., Mottram, J. C., & Fasel, N. (2002b). Cell death in *Leishmania* induced by stress and differentiation: programmed cell death or necrosis? *Cell Death & Differentiation*, 9(10), 1126–1139. <https://doi.org/10.1038/sj.cdd.4401071>
- Zhang, W.-W., Lypaczewski, P., & Matlashewski, G. (2020a). *Application of CRISPR/Cas9-Mediated Genome Editing in Leishmania* (pp. 199–224). https://doi.org/10.1007/978-1-0716-0294-2_14
- Zhang, W.-W., Lypaczewski, P., & Matlashewski, G. (2020b). *Application of CRISPR/Cas9-Mediated Genome Editing in Leishmania* (pp. 199–224). https://doi.org/10.1007/978-1-0716-0294-2_14
- Zhang, W.-W., & Matlashewski, G. (2015). CRISPR-Cas9-Mediated Genome Editing in *Leishmania donovani*. *MBio*, 6(4). <https://doi.org/10.1128/mBio.00861-15>
- Zilberstein, D. (2021). Lysosome Sensing Is a Key Mechanism in *Leishmania* Intracellular Development. *Frontiers in Microbiology*, 12. <https://doi.org/10.3389/fmicb.2021.667807>

APPENDIX A

LIST OF PUBLICATIONS FROM THESIS WORK

1. **Manash Sarma**, Vikash Kumar Dubey. Validating Glutathione Synthetase as a Therapeutic Target in *Leishmania donovani*: CRISPR-Cas9 Gene Knockout Studies. **(Manuscript under preparation)**
2. **Manash Sarma**, Kushal Bora, Preeti Ranjan, Vikash Kumar Dubey **(2024)** Identification of novel anti-leishmanials targeting Glutathione Synthetase of the parasite: A drug repurposing approach. **FEBS Letters** Volume 599, Issue 3 Pages: 295-455 <https://doi.org/10.1002/1873-3468.15016>
3. **Manash Sarma**, Subhomoi Borkotoky, Vikash Kumar Dubey **(2023)** Structure-based drug designing against *Leishmania donovani* using docking and molecular dynamics simulation studies: exploring glutathione synthetase as a drug target. **Journal of Biomolecular Structure and Dynamics**. Volume 42, 2024 - Issue 14 <https://doi.org/10.1080/07391102.2023.2240429>

LIST OF PUBLICATIONS FROM COLLABORATION

1. Shiv Kumar, **Manas Sarma**, Ehasanullah Khan and Vikash Kumar Dubey (2025). Investigating the Function of UVRAG in Regulation of Apoptosis & Autophagy and Its Implications in Cancer. *International Journal of Biological Macromolecules*, Volume 320, Part 2:145847 <https://doi.org/10.1016/j.ijbiomac.2025.145847>
2. Preeti Ranjan, **Manash Sarma**, Vikash Kumar Dubey **(2024)** Biochemical and biophysical characterization of *Leishmania donovani* citrate synthase. **International Journal of Biological Macromolecules**, Volume 279, Part 3:135400 <https://doi.org/10.1016/j.ijbiomac.2024.135400>
3. Kushal Bora, **Manash Sarma**, Shankar Prasad Kanaujia, Vikash Kumar Dubey **(2024)** Development of novel dual-target drugs against visceral leishmaniasis and combinational study with miltefosine. **Free Radical Biology and Medicine**. Volume 225, Pages 275-285 <http://dx.doi.org/10.1016/j.freeradbiomed.2024.10.257>
4. Kushal Bora, **Manash Sarma**, Shankar Prasad Kanaujia, Vikash Kumar Dubey **(2023)** Dual-target drugs against *Leishmania donovani* for potential novel therapeutics. **Scientific Reports**. 2023 Oct 26;13(1):18363. <https://doi.org/10.1038/s41598-023-45448-x>

APPENDIX B

CONFERENCES

1. Attended and presented a poster presentation at the FEBS-IUBMB-ENABLE 2024 conference on **Artificial Intelligence Reshaping Biomedical and Healthcare Research 4–6 December 2024 Nanyang Technological University (NTU), Singapore**. Title of the poster: “Identification of novel anti-leishmanial targeting glutathione synthetase of the parasite: A drug repurposing approach”.
2. Attended and presented a poster presentation at the International **Conference on Drug Discovery. November 10th & 11th, 2022. BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE, Goa**. Title of the poster: “In silico investigations in Glutathione synthetase of Leishmania donovani as a new therapeutic strategy for anti-leishmanial drug development”
3. Attended the **INDO-US CONFERENCE ON BIOENGINEERING AND REGENERATIVE MEDICINE ICBR, February 27th-29th, 2020**. Indian Institute of Technology (Banaras Hindu University)